Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

  • Increased cutting speed of 25,000 cuts per minute1 is designed to minimize retinal traction,2 increase vitreous flow1 and reduce infusion pressure fluctuations when used with Adaptive Fluidics.3*
  • Bi-Blade+ provides an average flow rate increase of 25%, enabling more efficient vitreous removal compared to Bi-Blade®.1*†
  • The resulting stability, efficiency and control help boost confidence for retina surgeons to deliver exceptional patient outcomes.

VAUGHAN, Ontario–(BUSINESS WIRE)–
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European launch of the Bi-Blade+ advanced dual-port vitrectomy cutter on the Stellaris Elite® Vision Enhancement System.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507552089/en/

“The launch of Bi-Blade+ is the latest example of our commitment to delivering meaningful innovation in Europe,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “Stellaris Elite has long been relied upon by European surgeons, and the 2024 Adaptive Fluidics software upgrade further enhanced the precise control and efficiency of the platform. We’re confident that the addition of Bi-Blade+ will also deliver meaningful benefits to retina surgeons and their patients.”

Bi-Blade+ provides an increased flow rate of 25%, enabling more efficient vitreous removal compared to Bi-Blade.1* At maximum speed, Bi-Blade+ also demonstrates a 62% reduction in cutter vibration compared to Bi-Blade, offering the surgeon optimized feel and comfort toward a stable surgical experience.4

Adaptive Fluidics automates fluid infusion to the eye in response to real-time vacuum commands from the surgeon, delivering precise and responsive fluidics infusion at every step of a vitrectomy procedure.

These two technologies combine to support and maintain IOP stability and control. When combined with Adaptive Fluidics, Bi-Blade+ demonstrated a 62% reduction in average infusion pressure compared to surgeries in which Adaptive Fluidics was not used.3 Continuous aspiration also provides consistent intraocular pressure (IOP) stability.3* In one study, use of Bi-Blade+ with Adaptive Fluidics resulted in a significant improvement in chamber IOP at a range closer to physiologic IOP (10 – 20 mmHg) even during high vacuum levels.3**

“The higher cut rate of Bi-Blade+ offers a significant advantage when removing vitreous,” said Professor Marco Mura, MD, University of Ferrara, Ferrara, Italy. “The ability to increase flow rate while maintaining a small sphere of influence and calm environment means surgeons can have more confidence when working close to the retina.”

*Based on ex vivo and in vitro testing.

**Based on ex vivo and in vitro testing comparing original Bi-Blade to single-port cutter.

Bi-Blade® is a trademark of Medical Instrument Development Laboratories, Inc. and is used by Bausch + Lomb under license.

Bi-Blade™+ Indications and Important Safety Information

Indications and Intended Use: The Bausch + Lomb vitrectomy cutter pouches are intended to cut and remove vitreous from the eye. They are indicated for any ocular condition requiring anterior vitrectomy during anterior segment surgery and for any vitreoretinal condition requiring vitrectomy during posterior or combined surgery.

Compatible Equipment: Stellaris Elite Bi-Blade+ accessories are only intended to operate with Bausch + Lomb Stellaris Elite vision enhancement systems with Bi-Blade+ procedure pack compatibility.

Known residual risks and complications include but are not limited to: infection; inflammation; ocular damage; trauma; cataract formation (not applicable in cataract removal procedures); foreign body/particulates in eye; intraocular pressure (IOP) variance that may cause damage to patient’s eye; visual impairment; ischemia; allergic reaction; edema.

ATTENTION: See the Instructions for Use for detailed directions, proper use, and full risk and safety information.

CAUTION: Federal (U.S.) Law restricts this device to sale, by or on the order of a physician.

About Bausch + Lomb

Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

Forward-looking Statements

This news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements may generally be identified by the use of the words “anticipates,” “seeks,” “expects,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “potential,” “pending” or “proposed” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

References

  1. Heuer R, Papour A, Higgins G. Vitrectomy flow performance and optimized system settings for retina shaving with 25g, 25,000cpm dual-action vitrectomy probes. Poster presented at: ARVO conference; May 2025; Salt Lake City, UT.

  2. Higgins G, Papour A. Comparison of traction, sphere of influence, and pulsatile flow in-vitro vitrectomy using 25 ga 25,000 CPM dual action vitrectomy probes and 25ga 7,500 CPM single action vitrectomy probes. Poster presented at: ARVO conference; May 2025; Salt Lake City, UT.

  3. Papour A, Hosten L. Intraocular pressure (IOP) optimized performance settings with posterior adaptive fluidics (PAF), and 25 gauge 25,000 cpm dual-action vitrectomy cutters. Invest Ophthalmol Vis Sci. 2024;65(7). Association for Research in Vision and Ophthalmology 2024 abstract 914.

  4. Data on file.

© 2026 Bausch + Lomb.

BBL.0008.USA.26

Media Contact:

Caryn Marshall

[email protected]

(908) 493-1381

Investor Contact:

George Gadkowski

[email protected]

(877) 354-3705 (toll free)

(908) 927-0735

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Health Optical Surgery

MEDIA:

Photo
Photo
Logo
Logo

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026

Progressing NMRA-511 in Alzheimer’s disease agitation and NMRA-898 in schizophrenia with clinical data expected for each program in the second half of 2026

Strong financial position with $147.1 million in cash and cash equivalents expected to support operations into the third quarter of 2027

WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.

“We focused on steady execution during the first quarter, highlighted by the full enrollment of the navacaprant KOASTAL‑2 and ‑3 studies with more than 400 patients per study. We look forward to the topline readout of these studies this quarter,” said Paul L. Berns, chairman and chief executive officer, Neumora. “Additionally, we reported the Phase 1b study with NMRA-511 demonstrating an unsurpassed clinical effect in Alzheimer’s disease agitation and we remain on track to report data from the MAD expansion cohort in the second half of 2026, with a Phase 2 study anticipated to begin in the first quarter of 2027.”

“The Phase 1 study for NMRA‑898 is ongoing, with data expected in the second half of 2026, and we are advancing NMRA‑215, which is expected to enter the clinic in the first quarter of 2027, reflecting the breadth and continued momentum of our pipeline. With a strong balance sheet, we believe we are well positioned to execute on these planned milestones and to continue progressing our portfolio in a disciplined manner,” continued Mr. Berns.

KEY PIPELINE HIGHLIGHTS


Navacaprant (Kappa Opioid Receptor Antagonist): Joint KOASTAL-2 and -3 Readout Expected in Second Quarter of 2026


The KOASTAL-2 and -3 studies were fully enrolled in the first quarter of 2026 with more than 400 patients in each study. The Company expects a joint topline data readout for KOASTAL-2 and -3 in the second quarter of 2026, including topline data for each study as well as pre-specified analyses with more than 450 patients enrolled after study optimizations in early 2025.


NMRA-511 (Vasopressin 1a Receptor Antagonist): On Track to Report Data from MAD Expansion Cohort in Alzheimer’s Disease (AD) Agitation in Second Half of 2026


In the first quarter of 2026, Neumora announced results from its Phase 1b signal-seeking study of NMRA-511 demonstrating an unsurpassed effect size and a favorable tolerability and safety profile with no reports of somnolence or sedation in people with AD agitation. Neumora plans to report data from a multiple ascending dose (MAD) expansion cohort evaluating higher doses of NMRA-511 in the second half of 2026 and to initiate a Phase 2 study with NMRA-511 in Alzheimer’s disease agitation in the first quarter of 2027.


NMRA-898 (M4 Positive Allosteric Modulator): Phase 1 Data Expected in Second Half of 2026


Neumora is conducting a MAD study with NMRA-898 in healthy volunteers and patients with stable schizophrenia. The goal of the study is to identify a maximum tolerated dose of NMRA-898 and confirm central nervous system penetration via cerebrospinal fluid exposure. The Company expects to report data from the study in the second half of 2026.


NMRA-215 (NLRP3 Inhibitor): Preclinical Work Ongoing; Program Update Expected in the Second Half of 2026


Neumora is developing NMRA-215 for the treatment of obesity. The Company expects to provide a program update in the second half of 2026 and for the program to enter the clinic in the first quarter of 2027.

FIRST QUARTER 2026 FINANCIAL RESULTS

  • Cash Position: As of March 31, 2026, Neumora had cash and cash equivalents of $147.1 million.
  • Financial Guidance: The Company expects that its cash and cash equivalents as of March 31, 2026, will enable it to fund its operating plan into the third quarter of 2027.
  • R&D Expense: Research and development expenses for the first quarter of 2026 were $38.6 million, as compared to $52.2 million for the same period in 2025. The decrease was primarily due to a reduction in clinical trial costs, and lower personnel-related costs.
  • G&A Expense: General and administrative expenses for the first quarter of 2026 were $14.3 million, as compared to $18.8 million for the same period in 2025. The decrease was primarily attributable to lower personnel-related costs.
  • Net Loss: The Company reported a net loss of $53.5 million for the first quarter of 2026, as compared to $68.0 million for the same period in 2025.

About Neumora

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients; the timing, progress and plans for its therapeutic development programs, including the timing of clinical trial initiation and data readouts, including for the KOASTAL-2 and KOASTAL-3, NMRA-215, NMRA-511 and NMRA-898 studies; support for continued development, and upcoming milestones and catalysts; expectations and projections regarding future operating results and financial performance, including the sufficiency of its cash resources and expectation of the timing of its cash runway; and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results to be materially different from the information expressed or implied by these forward-looking statements, including, among others: comparisons to efficacy results from other sponsors should be interpreted with caution due to differences in compounds, study designs, subject characteristics, and other factors that may limit direct comparability; the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in our clinical trials; risks related to our reliance on third parties, including CROs; risks related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora’s business in general, please refer to the risk factors identified in the Company’s filings with the Securities and Exchange Commission (SEC), including but not limited to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 which was filed with the SEC on or about the date hereof. Forward-looking statements speak only as of the date hereof, and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements. Our results for the quarter ended March 31, 2026 are also not necessarily indicative of our operating results for any future periods.

Financial Tables

NEUMORA THERAPEUTICS, INC.
Unaudited Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
         
    Three Months Ended

March 31,
      2026       2025  
Operating expenses:        
Research and development   $ 38,598     $ 52,151  
General and administrative     14,266       18,785  
Total operating expenses     52,864       70,936  
Loss from operations     (52,864 )     (70,936 )
Other income (expense):        
Interest income     1,231       3,074  
Interest expense     (1,854 )      
Other income (expense), net     59       (25 )
Total other income (expense)     (564 )     3,049  
Net loss before income taxes     (53,428 )     (67,887 )
Provision for income taxes     30       105  
Net loss   $ (53,458 )   $ (67,992 )
Other comprehensive loss:        
Unrealized loss on marketable securities           (65 )
Comprehensive loss   $ (53,458 )   $ (68,057 )
Net loss per share, basic and diluted   $ (0.30 )   $ (0.42 )
Weighted-average shares outstanding, basic and diluted     179,872       161,451  

Unaudited Condensed Consolidated Balance Sheets
(in thousands)
         
    March 31,

2026
  December 31,

2025
Cash and cash equivalents   $ 147,072   $ 182,530
Total assets   $ 153,877   $ 191,047
Total liabilities   $ 83,197   $ 87,176
Total stockholders’ equity   $ 70,680   $ 103,871



Neumora Contact:


Helen Rubinstein
617-402-5700
[email protected]



Unity Reports First Quarter 2026 Financial Results

Unity Reports First Quarter 2026 Financial Results

SAN FRANCISCO–(BUSINESS WIRE)–
Unity (NYSE: U), the world’s leading game engine, today announced financial results for the first quarter ended March 31, 2026.

“We are delivering exceptional revenue growth and margin expansion while executing on the most exciting product roadmap in Unity’s history,” said Matt Bromberg, President & CEO of Unity. “More games, more creators, and more game discovery are all fueling the growth in our business.”

Select revenue highlights for Q1 2026 are as follows:

 

Three Months Ended March 31,

 

 

2026

2025

YoY Change

Total Revenue

$508,238

$435,000

17%

Strategic Grow Revenue

$278,681

$186,934

49%

Strategic Create Revenue

$153,734

$133,309

15%

Total Strategic Revenue

$432,415

$320,243

35%

Non-Strategic Revenue1

$75,823

$114,757

(34)%

1 Consists primarily of revenue from (i) our ironSource Ad network, which was sunsetted effective April 30, 2026, and (ii) our Supersonic publishing business which we intend to divest.

Q2 2026 Guidance2

  • Total Revenue of $505 million to $515 million.

  • Strategic Revenue of $455 million to $465 million, up 29% – 32% year-over-year

    • Strategic Grow Revenue of $302 million to $306 million, up 50% – 52% year-over-year

    • Strategic Create Revenue of $154 million to $158 million up 11% – 14% year-over-year, when excluding the impact of a $12 million one-time revenue item in the second quarter of 2025.

  • Adjusted EBITDA of $130 million to $135 million, up 44% – 49% year-over-year

2 These statements are forward-looking and actual results may differ materially. Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

 

We have not reconciled our estimates for non-GAAP financial measures in this press release and in the earnings call referencing this press release to GAAP due to the uncertainty and potential variability of expenses that may be incurred in the future. As a result, a reconciliation is not available without unreasonable effort and we are unable to address the probable significance of the unavailable information. We have provided a reconciliation of other GAAP to non-GAAP financial measures in the financial statement tables for our first quarter non-GAAP results included in this press release.

 

Earnings Webcast

Unity will hold a public webcast at 8:30 a.m. ET today to discuss the results for its first quarter 2026. The live public webcast can be accessed on Unity’s Investor Relations website at https://investors.unity.com. The webcast replay will also be available on the site.

First Quarter 2026 Results:

Total Revenue Highlights:

  • Revenue was $508 million, compared to $435 million in the first quarter 2025.

  • Create Solutions revenue was $157 million, compared to $150 million in the first quarter 2025.

  • Grow Solutions revenue was $352 million, compared to $285 million in the first quarter 2025.

Profitability Highlights:

  • GAAP net loss was $347 million, with a margin of (68)%; GAAP basic and diluted net loss per share was $0.80.

  • Adjusted EBITDA was $138 million, with a margin of 27%; adjusted EPS was $0.23.

  • Net cash provided by operating activities was $71 million; free cash flow was $66 million.

Revenue

Revenue was $508 million, up 17% year-over-year. Strategic revenue was $432 million, up 35% year-over-year.

Create Solutions revenue was $157 million, up 4% year-over-year. The increase was driven by increases in subscription revenue, partially offset by decreases in cloud and hosting services revenue, driven by our portfolio reset in 2025.

Grow Solutions revenue was $352 million, up 24% year-over-year. The change was due to growth in the Unity Ad Network, driven by “Unity Vector”, partially offset by decreases in the IronSource Ad Network.

Basic and Diluted Net Loss per share

Basic and diluted net loss per share was $0.80, as compared to $0.19 for the same period in 2025.

Net Loss and Net Cash Provided by Operating Activities

Net Loss for the quarter was $347 million, which includes $279 million of impairment charges, related to the sunset of the ironSource Ads Network, and planned divestiture of our Supersonic game publishing business. This compares to a net loss of $78 million in the first quarter of 2025.

Net Loss margin was (68)%, compared to (18)% in the first quarter of 2025.

Net cash provided by operating activities for the quarter was $71 million, compared to $13 million in the first quarter of 2025.

Adjusted EBITDA, Free Cash Flow, and Adjusted EPS

Adjusted EBITDA for the quarter was $138 million, with a margin of 27%, compared to $84 million in the first quarter of 2025, with a margin of 19%. The year-over-year improvement was driven by higher revenue and continued cost control.

Free cash flow for the quarter was $66 million, compared to $7 million in the first quarter of 2025.

Adjusted EPS for the quarter was $0.23, compared to $0.24 in the first quarter of 2025.

Liquidity

As of March 31, 2026, our cash and cash equivalents, and restricted cash was $2,146 million, and increased by $82 million, as compared with $2,064 million as of December 31, 2025. This increase was primarily driven by our operations.

About Unity

Unity [NYSE: U] offers a suite of tools to develop, deploy, and grow games and interactive experiences across all major platforms from mobile, PC, and console, to extended reality. For more information, visit Unity.com.

 

UNITY SOFTWARE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)

 

 

 

 

As of

 

March 31, 2026

December 31, 2025

Assets

 

 

Current assets:

 

 

Cash and cash equivalents

$

2,140,861

 

$

2,055,840

 

Accounts receivable, net

 

654,003

 

 

643,611

 

Prepaid expenses and other

 

128,467

 

 

113,012

 

Total current assets

 

2,923,331

 

 

2,812,463

 

Property and equipment, net

 

54,314

 

 

68,289

 

Goodwill

 

3,166,304

 

 

3,166,304

 

Intangible assets, net

 

262,624

 

 

650,544

 

Other assets

 

115,168

 

 

140,006

 

Total assets

$

6,521,741

 

$

6,837,606

 

Liabilities and stockholders’ equity

 

 

Current liabilities:

 

 

Accounts payable

$

8,648

 

$

13,981

 

Accrued expenses and other

 

313,155

 

 

299,541

 

Publisher payables

 

393,016

 

 

431,494

 

Deferred revenue

 

229,506

 

 

224,405

 

Current portion of convertible notes

 

556,810

 

 

556,451

 

Total current liabilities

 

1,501,135

 

 

1,525,872

 

Convertible notes

 

1,679,560

 

 

1,678,899

 

Long-term deferred revenue

 

16,831

 

 

14,038

 

Other long-term liabilities

 

83,091

 

 

122,660

 

Total liabilities

 

3,280,617

 

 

3,341,469

 

Commitments and contingencies

 

 

Redeemable noncontrolling interests

 

259,168

 

 

252,637

 

Stockholders’ equity:

 

 

Common stock, $0.000005 par value:

 

 

Authorized shares – 1,000,000 and 1,000,000

 

 

Issued and outstanding shares – 436,401 and 432,860

 

2

 

 

2

 

Additional paid-in capital

 

7,461,858

 

 

7,378,295

 

Accumulated other comprehensive loss

 

257

 

 

(2,156

)

Accumulated deficit

 

(4,486,319

)

 

(4,138,709

)

Total Unity Software Inc. stockholders’ equity

 

2,975,798

 

 

3,237,432

 

Noncontrolling interest

 

6,158

 

 

6,068

 

Total stockholders’ equity

 

2,981,956

 

 

3,243,500

 

Total liabilities and stockholders’ equity

$

6,521,741

 

$

6,837,606

 

 

UNITY SOFTWARE INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except per share amounts)

(Unaudited)

 

 

 

 

Three Months Ended

 

March 31,

 

2026

2025

Revenue

$

508,238

 

$

435,000

 

Cost of revenue

 

351,637

 

 

113,957

 

Gross profit

 

156,601

 

 

321,043

 

Operating expenses

 

 

Research and development

 

254,425

 

 

220,625

 

Sales and marketing

 

195,377

 

 

162,013

 

General and administrative

 

58,212

 

 

66,340

 

Total operating expenses

 

508,014

 

 

448,978

 

Loss from operations

 

(351,413

)

 

(127,935

)

Interest expense

 

(6,020

)

 

(5,891

)

Interest income and other income (expense), net

 

3,464

 

 

58,111

 

Loss before income taxes

 

(353,969

)

 

(75,715

)

Provision for (benefit from) Income taxes

 

(7,042

)

 

2,192

 

Net loss

 

(346,927

)

 

(77,907

)

Net income (loss) attributable to noncontrolling interest and redeemable noncontrolling interests

 

683

 

 

(265

)

Net loss attributable to Unity Software Inc.

 

(347,610

)

 

(77,642

)

Basic and diluted net loss per share attributable to Unity Software Inc.

$

(0.80

)

$

(0.19

)

Weighted-average shares used in computation of basic and diluted net loss per share

 

434,255

 

 

411,852

 

 

 

 

Net loss

 

(346,927

)

 

(77,907

)

Change in foreign currency translation adjustment

 

3,048

 

 

1,178

 

Comprehensive loss

$

(343,879

)

$

(76,729

)

Net income (loss) attributable to noncontrolling interest and redeemable noncontrolling interests

 

683

 

 

(265

)

Foreign currency translation attributable to noncontrolling interest and redeemable noncontrolling interests

 

635

 

 

254

 

Comprehensive income (loss) attributable to noncontrolling interest and redeemable noncontrolling interests

 

1,318

 

 

(11

)

Comprehensive loss attributable to Unity Software Inc.

$

(345,197

)

$

(76,718

)

 

UNITY SOFTWARE INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

 

Three Months Ended

 

March 31,

 

2026

2025

Operating activities

 

 

Net loss

$

(346,927

)

$

(77,907

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

Depreciation and amortization

 

127,255

 

 

96,217

 

Stock-based compensation expense

 

77,165

 

 

98,790

 

Gain on repayment of convertible note

 

 

 

(42,744

)

Impairment of intangible assets

 

270,506

 

 

 

Impairment of property and equipment

 

8,422

 

 

3,470

 

Impairment of investments

 

15,000

 

 

 

Other

 

1,469

 

 

(218

)

Changes in assets and liabilities, net of effects of acquisitions:

 

 

Accounts receivable, net

 

(10,196

)

 

21,022

 

Prepaid expenses and other

 

(18,398

)

 

(10,602

)

Other assets

 

9,334

 

 

10,023

 

Accounts payable

 

(5,238

)

 

2,198

 

Accrued expenses and other

 

13,960

 

 

(21,029

)

Publisher payables

 

(38,478

)

 

(55,155

)

Other long-term liabilities

 

(39,947

)

 

(10,919

)

Deferred revenue

 

7,359

 

 

(120

)

Net cash provided by operating activities

 

71,286

 

 

13,026

 

Investing activities

 

 

Purchases of non-marketable investments

 

 

 

 

Purchases of intangible assets

 

 

 

 

Purchases of property and equipment

 

(4,829

)

 

(5,718

)

Net cash used in investing activities

 

(4,829

)

 

(5,718

)

Financing activities

 

 

Proceeds from issuance of convertible notes

 

 

 

690,000

 

Purchase of capped calls

 

 

 

(44,436

)

Payment of debt issuance costs

 

 

 

(13,236

)

Repayments of convertible note

 

 

 

(641,691

)

Proceeds from issuance of common stock upon exercise of stock options and purchase of ESPP shares

 

11,643

 

 

21,611

 

Net cash provided by financing activities

 

11,643

 

 

12,248

 

Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash

 

3,688

 

 

4,197

 

Increase in cash, cash equivalents, and restricted cash

 

81,788

 

 

23,753

 

Cash, cash equivalents, and restricted cash, beginning of period

 

2,064,301

 

 

1,527,881

 

Cash, cash equivalents, and restricted cash, end of period

$

2,146,089

 

$

1,551,634

 

 

About Non-GAAP Financial Measures

To supplement our consolidated financial statements prepared and presented in accordance with generally accepted accounting principles in the United States (GAAP) we use certain non-GAAP financial measures, as described below, to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe the following non-GAAP measures are useful in evaluating our operating performance. We are presenting these non-GAAP financial measures because we believe, when taken collectively, they may be helpful to investors because they provide consistency and comparability with past financial performance.

However, non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. As a result, our non-GAAP financial measures are presented for supplemental informational purposes only and should not be considered in isolation or as a substitute for our consolidated financial statements presented in accordance with GAAP.

We define adjusted EBITDA as GAAP net income or loss excluding benefits or expenses associated with stock-based compensation, amortization and impairment of acquired intangible assets, depreciation, restructurings and reorganizations, interest, income tax, and other non-operating activities, which primarily consist of foreign exchange rate gains or losses. We define adjusted EBITDA margin as adjusted EBITDA as a percentage of revenue. We define adjusted gross profit as GAAP gross profit excluding expenses associated with stock-based compensation, amortization and impairment of acquired intangible assets, depreciation, and restructurings and reorganizations. We define adjusted gross margin as adjusted gross profit as a percentage of revenue.

We define adjusted cost of revenue as GAAP cost of revenue, excluding expenses associated with stock-based compensation, amortization and impairment of acquired intangible assets, depreciation, and restructurings and reorganizations. We define adjusted research and development expense as research and development expense, excluding expenses associated with stock-based compensation, amortization and impairment of acquired intangible assets, depreciation, and restructurings and reorganizations. We define adjusted sales and marketing expense as GAAP sales and marketing expense, excluding expenses associated with stock-based compensation, amortization and impairment of acquired intangible assets, depreciation, and restructurings and reorganizations. We define adjusted general and administrative expense as general and administrative expense excluding expenses associated with stock-based compensation, depreciation, and restructurings and reorganizations. We define free cash flow as net cash provided by operating activities less cash used for purchases of property and equipment.

We define adjusted EPS as net income or loss excluding benefits or expenses associated with stock-based compensation, amortization and impairment of acquired intangible assets, depreciation, restructurings and reorganizations, and the income tax impact of the preceding adjustments (cumulatively “adjusted net income”), increased by the tax effected impacts from any relevant dilutive securities, divided by the diluted weighted-average outstanding shares. The effective tax rate used in calculating adjusted EPS is estimated for each period, based on the net income or loss adjusted for the items noted above, and may differ from the effective rate used in our financial statements. Shares of common stock that are excluded in our calculation of GAAP diluted net loss per share due to their antidilutive impact on such calculations, are included in the diluted weighted average outstanding shares used in our calculation of adjusted EPS, to the extent they have a dilutive impact on adjusted EPS given the adjusted net income in each period.

 

UNITY SOFTWARE, INC.

Non-GAAP Reconciliation

(In thousands)

 

 

 

 

Three Months Ended

 

March 31,

 

2026

2025

 

 

 

Adjusted EBITDA reconciliation

 

 

Revenue

$

508,238

 

$

435,000

 

GAAP net loss

$

(346,927

)

$

(77,907

)

Add:

 

 

Stock-based compensation expense

$

76,869

 

$

95,316

 

Amortization of intangible assets expense

$

117,414

 

$

85,650

 

Depreciation expense

$

9,841

 

$

10,567

 

Impairment of intangible assets

$

278,666

 

$

 

Restructuring and reorganization costs

$

6,903

 

$

20,345

 

Interest expense

$

6,020

 

$

5,891

 

Interest income and other income (expense), net

$

(3,464

)

$

(58,111

)

Provision for (benefit from) income taxes

$

(7,042

)

$

2,192

 

Adjusted EBITDA

$

138,280

 

$

83,943

 

GAAP net loss margin

 

(68

)%

 

(18

)%

Adjusted EBITDA margin

 

27

%

 

19

%

 

 

 

Adjusted gross profit reconciliation

 

 

GAAP gross profit

$

156,601

 

$

321,043

 

Add:

 

 

Stock-based compensation expense

 

7,382

 

 

9,112

 

Amortization of intangible assets expense

 

27,069

 

 

26,700

 

Depreciation expense

 

1,631

 

 

1,714

 

Impairment of intangible assets

 

226,516

 

 

 

Restructuring and reorganization costs

 

(53

)

 

534

 

Adjusted gross profit

$

419,146

 

$

359,103

 

GAAP gross margin

 

31

%

 

74

%

Adjusted gross margin

 

82

%

 

82

%

 

 

 

Operating expenses reconciliation

 

 

Cost of revenue

 

 

GAAP cost of revenue

$

351,637

 

$

113,957

 

Stock-based compensation expense

 

(7,382

)

 

(9,112

)

Amortization of intangible assets expense

 

(27,069

)

 

(26,700

)

Depreciation expense

 

(1,631

)

 

(1,714

)

Impairment of intangible assets

 

(226,516

)

 

 

Restructuring and reorganization costs

 

53

 

 

(534

)

Adjusted cost of revenue

$

89,092

 

$

75,897

 

GAAP cost of revenue as a percentage of revenue

 

69

%

 

26

%

Adjusted cost of revenue as a percentage of revenue

 

18

%

 

18

%

 

 

 

Research and development

 

 

GAAP research and development expense

$

254,425

 

$

220,625

 

Stock-based compensation expense

 

(38,628

)

 

(50,595

)

Amortization of intangible assets expense

 

(51,378

)

 

(16,530

)

Depreciation expense

 

(4,792

)

 

(5,266

)

Impairment of intangible assets

 

(3,998

)

 

 

Restructuring and reorganization costs

 

(3,576

)

 

(8,346

)

Adjusted research and development expense

$

152,053

 

$

139,888

 

GAAP research and development expense as a percentage of revenue

 

50

%

 

51

%

Adjusted research and development expense as a percentage of revenue

 

30

%

 

32

%

 

 

 

Sales and marketing

 

 

GAAP sales and marketing expense

$

195,377

 

$

162,013

 

Stock-based compensation expense

 

(14,172

)

 

(16,486

)

Amortization of intangible assets expense

 

(38,967

)

 

(42,420

)

Depreciation expense

 

(2,013

)

 

(2,154

)

Impairment of intangible assets

 

(46,969

)

 

 

Restructuring and reorganization costs

 

(2,314

)

 

(7,900

)

Adjusted sales and marketing expense

$

90,942

 

$

93,053

 

GAAP sales and marketing expense as a percentage of revenue

 

38

%

 

37

%

Adjusted sales and marketing expense as a percentage of revenue

 

18

%

 

21

%

 

 

 

General and administrative

 

 

GAAP general and administrative expense

$

58,212

 

$

66,340

 

Stock-based compensation expense

 

(16,687

)

 

(19,123

)

Depreciation expense

 

(1,405

)

 

(1,433

)

Impairment of intangible assets

 

(1,183

)

 

 

Restructuring and reorganization costs

 

(1,066

)

 

(3,565

)

Adjusted general and administrative expense

$

37,871

 

$

42,219

 

GAAP general and administrative expense as a percentage of revenue

 

12

%

 

15

%

Adjusted general and administrative expense as a percentage of revenue

 

7

%

 

10

%

 

 

 

Adjusted EPS reconciliation

 

 

GAAP net loss

$

(346,927

)

$

(77,907

)

Stock-based compensation expense

 

76,869

 

 

95,316

 

Amortization of intangible assets expense

 

117,414

 

 

85,650

 

Depreciation expense

 

9,841

 

 

10,567

 

Impairment of intangible assets

 

278,666

 

 

 

Restructuring and reorganization costs

 

6,903

 

 

20,345

 

Income tax impact of adjusting items

 

(37,534

)

 

(27,764

)

Adjusted net income used for calculation of adjusted EPS, before impact of dilutive instruments

$

105,232

 

$

106,207

 

Increase from forgone financing costs on dilutive convertible notes, net of tax

 

4,668

 

 

4,597

 

Adjusted net income used for calculation of adjusted EPS, including impact of dilutive instruments

$

109,900

 

$

110,804

 

 

 

 

Weighted-average common shares used in GAAP diluted net loss per share attributable to Unity Software Inc.

 

434,255

 

 

411,852

 

Convertible notes

 

41,348

 

 

30,494

 

Stock options and PVOs

 

2,941

 

 

6,863

 

Unvested RSUs, PVUs, and PSUs

 

6,805

 

 

5,166

 

ESPP

 

127

 

 

650

 

Non-GAAP weighted-average common shares used in adjusted EPS

 

485,476

 

 

455,025

 

 

 

 

GAAP diluted net loss per share attributable to Unity Software Inc.

 

(0.80

)

 

(0.19

)

Total impact on diluted net loss per share attributable to Unity Software Inc. from non-GAAP adjustments

 

1.04

 

 

0.45

 

Total impact on diluted net loss per share attributable to Unity Software Inc. from antidilutive common stock now included

 

(0.01

)

 

(0.02

)

Adjusted EPS

 

0.23

 

 

0.24

 

 

 

 

Free cash flow reconciliation

 

 

Net cash provided by operating activities

$

71,286

 

$

13,026

 

Less:

 

 

Purchases of property and equipment

 

(4,829

)

 

(5,718

)

Free cash flow

 

66,457

 

 

7,308

 

 

 

 

Net cash used in investing activities

 

(4,829

)

 

(5,718

)

Net cash provided by financing activities

 

11,643

 

 

12,248

 

 

Cautionary Statement Regarding Forward-Looking Statements

This press release and the earnings call referencing this press release contain “forward-looking statements,” as that term is defined under federal securities laws, including statements regarding Unity’s outlook and future financial performance, including, but not limited to: (i) Unity’s ability to further enhance its platform, accelerate product innovation and enhance financial performance; (ii) expectations regarding Vector, including expectations regarding Vector’s improvements and performance and the expansion of Vector across both Create and Grow solutions; (iii) our strategic initiatives, including our continued investment and focus on artificial intelligence tools; (iv) expectations regarding Vector leveraging behavioral data available through Unity Runtime, including expectations of multi-year growth of the product portfolio and its impact on financial results; (v) statements regarding our product roadmap, products, projects, technology and ongoing product development; (vi) expectations regarding growth of Vector and its impact on Unity’s overall growth prospects, as well as revenue mix; (vii) statements regarding industry trends and business model evolution; (viii) statements regarding our market opportunity; (ix) expectations regarding our competitive position and growth prospects; (x) expectations regarding improvements in operating margins; (xi) expectations regarding future profitability, including our expectation to become GAAP profitable by the fourth quarter of 2026; (xii) plans to pay off future obligations; and (xiii) Unity’s financial guidance for future periods. The words “aim,” “believe,” “may,” “will,” “estimate,” “continue,” “intend,” “expect,” “plan,” “project,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Risks include, but are not limited to, those related to: (i) the impact of macroeconomic conditions, such as inflation, high interest rates, tariffs, sanctions and trade barriers, and limited credit availability which could further cause economic uncertainty and volatility; (ii) Unity’s ability to compete effectively; (iii) adverse changes in the geopolitical relationship between the U.S. and China; (iv) Unity’s ability to develop, deploy, maintain, manage, or commercialize artificial intelligence-enabled products; (v) Unity’s ability to address issues raised by the development or use of artificial intelligence in its offerings, or the use of artificial intelligence by its customers, personnel, vendors and competitors; (vii) Unity’s ability to execute its plans to realign its business and to right-size its investments, including the sunset of the ironSource Ads Network and the planned divestiture of its Supersonic game publishing business; (vii) the impact of any decisions to change how Unity prices its products and services; (viii) Unity’s ability to achieve and sustain profitability; (ix) Unity’s ability to retain existing customers and expand the use of its platform, or attract new customers; (x) Unity’s ability to further expand into adjacent business areas or new industries; (xi) the impact of any changes of terms of service, policies or technical requirements from operating system platform providers or application stores which may result in changes to Unity or its customers’ business practices; (xii) Unity’s ability to maintain favorable relationships with hardware, operating system, device, game console and other technology providers; (xiii) breaches in its security measures, unauthorized access to its platform, data, or its customers’ or other users’ personal data; (xiv) Unity’s ability to manage growth effectively and manage costs effectively; (xv) the rapidly changing and increasingly stringent laws, regulations, contractual obligations and industry standards that relate to privacy, data security and the protection of children; (xvi) Unity’s ability to attract, manage and retain its talent; (xvii) Unity’s ability to adapt effectively to rapidly changing technology, evolving industry standards, changing regulations, or changing customer needs, requirements, or preferences; and (xviii) the effectiveness of Vector. Further information on these and additional risks that could affect our results is included in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed with the SEC on February 11, 2026 and our future reports that we may file with the SEC from time to time, which could cause actual results to vary from expectations. Copies of reports filed with the SEC are available on the Unity Investor Relations website. Statements herein speak only as of the date of this release, and Unity assumes no obligation to, and does not currently intend to, update any such forward looking statements after the date of this release except as required by law.

Source: Unity Software Inc.

Investor Relations:

Alex Giaimo, Head of Investor Relations

[email protected]

Media Relations:

[email protected]

KEYWORDS: California North America United States Ireland United Kingdom Europe

INDUSTRY KEYWORDS: Entertainment Technology Online Mobile Entertainment Software Metaverse Electronic Games

MEDIA:

Logo
Logo

Polestar reports Q1 2026 select financial and operational results

Polestar reports Q1 2026 select financial and operational results

  • Record first quarter volumes of 13,126 cars, a growth of 7% year-on-year

  • Largest product offensive launched: four new models planned in next three years

  • Performance impacted by intensified competition, EU and US tariffs, FX and seasonality offsetting continued cost reductions

  • Strengthened capital structure and improved liquidity position

  • Cash position of USD 676 million as of end Q1 2026

GOTHENBURG, Sweden–(BUSINESS WIRE)–
Polestar (Nasdaq: PSNY) reports select unaudited financial and operational results for the quarter ended March 31, 2026 (Q1 2026).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507811327/en/

Michael Lohscheller, Polestar CEO, said: “The first quarter saw us deliver strong volume growth in a very competitive market. With implemented steps to improve our cost base being offset by more challenging market conditions, we are accelerating efforts to adjust our business model, become leaner and improve manufacturing efficiencies.

“Commercially, our focus remains on scaling our business by expanding our retail network, especially in Europe, with plans to reach 250 sales points globally by the end of 2026. This will help us capitalise on our growing model line-up, which targets wider, more profitable segments. Deliveries of the new Polestar 4 variant are planned to start during the latter part of the year, closely followed by the all-new Polestar 2 in 2027 and thereafter Polestar 7 compact SUV.”

Key financial highlights

(in millions of U.S. dollars)

For the three months ended March 31,

 

 

2026

2025

Change, %

 

 

 

 

Retail sales, units

13,126

12,263

7.0

 

 

 

 

Revenue

633

632

0.2

Gross (Loss) / Profit

(20)

65

(130.8)

Gross margin, %

(3.2)%

10.3%

-13.5 ppts

Adjusted Gross (Loss) / Profit (non-GAAP) 1

(21)

65

(132.3)

Adjusted Gross Margin (non-GAAP) 1, %

(3.3)%

10.3%

-13.6ppts

Net loss

(383)

(166)

(130.7)

Adjusted EBITDA (non-GAAP) 1

(235)

(96)

(144.8)

(1)

Non-GAAP measures. See the reconciliation of non-GAAP metrics to the nearest GAAP measure in Appendix A.

  • Retail sales totaled an estimated 13,126 cars, up 7.0% YoY from 12,263 cars a year earlier, supported by continuous retail expansion, an attractive model line-up, and growing sales of Polestar 4.

  • Revenue of USD 633 million, up 0.2% from USD 632 million in the comparable period, driven predominantly by higher volumes and positive foreign exchange impact related to the pound sterling and euro movements against the U.S. dollar offset mainly by significant pressure on pricing, the product mix, which included fewer Polestar 3 cars but more Polestar 4 vehicles and lower carbon credits sales. Carbon credits sales totaled USD 21 million in the period down from USD 29 million a year earlier, of which USD 17 million was booked as revenue and USD 4 million was booked in other operating income.

  • Gross margin at (3.2)%, from 10.3% in Q1 2025, and Adjusted Gross Margin at (3.3)%, from 10.3% in Q1 2025, due mainly to further pressure on pricing, EU and US tariffs, lower carbon credits sales and one-off impacts, partially offset by growth in volumes, an increasing share of higher margin Polestar 4 in the product mix and continued product cost reduction.

  • Net loss of USD (383) million, compared to net loss of USD (166) million a year earlier, driven by gross loss result, and mainly the negative foreign exchange impact related to Chinese yuan movements on operating and financing liabilities. Selling, General and Administrative (SG&A) expenses were impacted by higher sales agent remuneration linked to growth of volumes, one-off personnel-related costs and the timing of marketing events despite ongoing strict cost discipline across SG&A; Research and Development (R&D) expenses were stable.

  • Adjusted EBITDA of USD (235) million, compared to adjusted EBITDA of USD (96) million in the comparable period, due mainly to gross loss result, factors mentioned above and negative foreign exchange movements on operating liabilities.

  • Cash position of USD 676 million compared to USD 1,159 million as of December 31, 2025. The change in the cash position was primarily driven by Adjusted EBITDA loss, net negative movement in working capital and net repayment of financing facilities offset by equity proceeds in the first quarter of 2026. While inventory levels reduced, this positive impact on working capital was more than offset by cash outflows from settlement of payables.

  • Further details are provided in the reconciliation table for non-GAAP measures in Appendix A.

Key operational highlights

The table below summarizes key operational highlights for the three months ended March 31, 2026:

 

For the three months ended March 31,

 

 

2026

 

2025

 

Change, %

Retail sales 1

13,126

 

12,263

 

7.0

  • including external vehicles with repurchase obligations

350

 

182

 

92.3

  • including internal vehicles

724

 

406

 

78.3

Markets2

28

 

27

 

+ 1 market

Sales points3,4

230

 

159

 

44.7

of which sales points, excluding China

230

 

154

 

49.4

Service points5

1,241

 

1,190

 

4.3

(1)

 

Retail sales figures are sales to end customers. Retail Sales include new cars handed over via all sales channels and all sales types, including but not restricted to internal, fleet, retail, rental and leaseholders’ channels across all markets irrespective of their market model and setup and may or may not generate revenue directly for Polestar.

(2)

 

Represents the markets in which Polestar operates.

(3)

 

Represents Sales Points, including retail locations which are physical facilities (such as showrooms), actively selling Polestar cars, and pre-space activations, which represent locations with an ongoing project to build a retail location that have already started selling Polestar cars.

(4)

 

In April 2025, Polestar signed an agreement to terminate the business of the Joint Venture and transfer the PRC distribution rights and certain assets from the JV to Polestar, so as to allow Polestar to resume direct sales, customer service and distribution activities in the Chinese market.

(5)

 

Represents Volvo Cars service centers to provide access to customer service points worldwide in support of Polestar’s international expansion.

  • Sales points continue to grow, as the transition to an active selling model continues and we ramp up retail expansion. In Q1 2026, Polestar opened 19 new retail sales points bringing the total to 230 sales points at the end of Q1 2026. During the same period, Polestar signed up 14 new retailers, to reach the total of 172 retail partners, an increase of 8.9% from the end of December 2025.

  • The increase in external sales with a repurchase obligation is primarily related to the commercial activity in the German market.

  • Polestar increased sales of internal cars to support its retail network expansion in Europe.

Key loan facilities and funding highlights

  • Over USD 1.4 billion worth of facilities renewed in Q1 2026

    • In February 2026, Green Trade Finance Facility (TFF) with a syndicate of global banks restructured and renewed for EUR 400 million. Additionally, approximately USD 570 million in working capital loans were renewed.

    • In March 2026, approx. USD 380 million in working capital facilities were renewed.

  • An additional EUR 50 million to Green Trade Finance Facility (TFF) has been credit-approved by Fubon Bank (Hong Kong) Limited, subject to completion of the relevant syndicate documentation.

  • As previously announced, during Q1 2026, Polestar secured a total of USD 0.7 billion of new equity from several financial institutions. Concurrent with their equity investments, these financial institutions each entered into a put option arrangement with a wholly-owned subsidiary of Geely Sweden Holdings AB. These equity investments consist of the following:

    • In February 2026, Polestar secured USD 400 million from Feathertop Funding Limited, a special purpose vehicle consolidated to Sumitomo Mitsui Banking Corporation, and Standard Chartered Bank (Hong Kong) Limited.

    • In March 2026, Polestar secured USD 300 million from investors including Credit Agricole CIB, Vida France S.A., Innovator Limited and Proximaster Holdings Company.

  • Geely Sweden and Volvo Cars agreed to convert approx. USD 639 million of loans outstanding to Polestar into equity with USD 274 million converted by Volvo Cars on March 31, 2026; Geely Sweden is expected to convert approx. USD 300 million and Volvo Cars is expected to convert approx. USD 65 million later in Q2 2026.

  • On March 31, 2026, Volvo Cars extended the remaining USD 726 million shareholder loan to December 2031.

As previously announced regarding the Company’s USD 950 million ‘Club loan’, by end of Q1 2026, the revenue and debt-to-asset ratio covenant tests have been agreed upon and amended for Q1 2026 and the remaining test periods of 2026.

The Company was in compliance with all its covenants as of March 31, 2026.

With the support from Geely Holding Group, we have implemented significant steps to strengthen our balance sheet and improve our debt and liquidity positions, and we continue to consider new equity and debt funding.

Conference call

Michael Lohscheller, CEO, and Jean-Francois Mady, CFO, will host a conference call today, May 7, 2026, at 14:00 CET. To join the call, please use this link https://edge.media-server.com/mmc/p/tii8h4jg or follow the instructions available under Events on the Polestar Investor Relations website.

Publication of UK Annual Report and Accounts

The Company’s UK Annual Report and Accounts has been published and is available to download via the Investor Relations website: https://investors.polestar.com/financial-information/annual-reports.

Notes

All financial figures are in millions of U.S. dollars (USD). Unless stated otherwise, the performance shown in this press release covers the three-month period ended March 31, 2026 (Q1 2026), compared to the three-month period ended March 31, 2025 (Q1 2025).

Calendar

Polestar expects to report its retail sales volumes for Q2 2026 on July 9, 2026.

About Polestar

Polestar (Nasdaq: PSNY) is the Swedish electric performance car brand with a focus on uncompromised design and innovation, and the ambition to accelerate the change towards a sustainable future. Headquartered in Gothenburg, Sweden, its cars are available in 28 markets globally across North America, Europe, and Asia Pacific.

Polestar has four models in its line-up: Polestar 2, Polestar 3, Polestar 4, and Polestar 5. Planned models include Polestar 4 new variant (to be introduced in the last quarter of 2026), Polestar 2 successor (to be launched early in 2027), Polestar 7 compact SUV (to be introduced in 2028) and the Polestar 6 roadster. With its vehicles currently manufactured on two continents, North America and Asia, Polestar is diversifying its manufacturing footprint further, with production of Polestar 7 planned in Europe.

Polestar has an unwavering commitment to sustainability and has set an ambitious roadmap to reach its climate targets: halve greenhouse gas emissions by 2030 per-vehicle-sold and become climate-neutral across its value chain by 2040. Polestar’s comprehensive sustainability strategy covers the four areas of Climate, Transparency, Circularity, and Inclusion.

Statement regarding unaudited financial and operational results

The unaudited financial and operational information published in this press release is subject to potential adjustments. Potential adjustments to operational and consolidated financial information may be identified from work performed during Polestar’s year-end audit. This could result in differences from the unaudited operational and financial information published herein. For the avoidance of doubt, the unaudited operational and financial information published in this press release should not be considered a substitute for the financial information filed with the SEC in Polestar’s Annual Reports on Form 20-F.

Forward-looking statements

Certain statements in this press release (“Press Release”) may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the future financial or operating performance of Polestar including the number of vehicle deliveries and gross margin. For example, projections of revenue, volumes, margins, cash flow break-even and other financial or operating metrics and statements regarding expectations of future needs for funding and plans related thereto are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “forecast”, “plan”, “seek”, “future”, “propose” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Polestar and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) Polestar’s ability to enter into or maintain agreements or partnerships with its strategic partners, including Volvo Cars and Geely, original equipment manufacturers, vendors and technology providers; (2) Polestar’s ability to maintain relationships with its existing suppliers, source new suppliers for its critical components and enter into longer term supply contracts and complete building out its supply chain; (3) Polestar’s ability to raise additional funding; (4) Polestar’s ability to successfully execute cost-cutting activities and strategic efficiency initiatives; (5) Polestar’s estimates of expenses, profitability, gross margin, cash flow, and cash reserves; (6) Polestar’s ability to continue to meet stock exchange listing standards; (7) changes in domestic and foreign business, market, financial, political and legal conditions; (8) demand for Polestar’s vehicles or car sale volumes, revenue and margin development based on pricing, variant and market mix, cost reduction efficiencies, logistics and growing aftersales; (9) delays in the expected timelines for the development, design, manufacture, launch and financing of Polestar’s vehicles and Polestar’s reliance on a limited number of vehicle models to generate revenues; (10) increases in costs, disruption of supply or shortage of materials, in particular for lithium-ion cells or semiconductors; (11) risks related to product recalls, regulatory fines and/or an unexpectedly high volume of warranty claims; (12) Polestar’s reliance on its partners to manufacture vehicles at a high volume, some of which have limited experience in producing electric vehicles, and on the allocation of sufficient production capacity to Polestar by its partners in order for Polestar to be able to increase its vehicle production volumes; (13) the ability of Polestar to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (14) risks related to future market adoption of Polestar’s offerings; (15) risks related to Polestar’s current distribution model and the evolution of its distribution model in the future; (16) the effects of competition and the high barriers to entry in the automotive industry and the pace and depth of electric vehicle adoption generally on Polestar’s future business; (17) changes in environmental laws, regulatory requirements (including existing regulations related to connected vehicles as well as impacts from potential or existing laws and regulations that may prevent the importation of certain electric vehicles into the US), governmental incentives, tariffs (including potentially higher than expected tariffs if customs authorities determine a vehicle does not qualify for a lower tariff due to the origin of component parts) and fuel and energy prices; (18) Polestar’s reliance on the development of vehicle charging networks to provide charging solutions for its vehicles and its strategic partners for servicing its vehicles and their integrated software; (19) Polestar’s ability to establish its brand and capture additional market share, and the risks associated with negative press or reputational harm, including from electric vehicle fires; (20) the outcome of any potential litigation, including litigation involving Polestar and Gores Guggenheim, Inc., government and regulatory proceedings, including the NHTSA investigation into the Polestar 2 rear view camera, tax audits, investigations and inquiries; (21) Polestar’s ability to continuously and rapidly innovate, develop and market new products; (22) the impact of the ongoing conflict between Ukraine and Russia and the conflict with Iran and the conflict in the Red Sea; and (23) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Polestar’s Form 20-F, and other documents filed, or to be filed, with the SEC by Polestar. There may be additional risks that Polestar presently does not know or that Polestar currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.

Nothing in this Press Release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Polestar assumes no obligation to update these forward-looking statements, even if new information becomes available in the future, except as may be required by law.

APPENDIX A

Polestar Automotive Holding UK PLC

Non-GAAP Financial Measures

Polestar uses both generally accepted accounting principles (“GAAP,” i.e., IFRS) and non-GAAP (i.e., non-IFRS) financial measures to evaluate operating performance and for other strategic and financial decision-making purposes. Polestar believes non-GAAP financial measures are helpful to investors as they provide useful perspective on underlying business trends and assist in period-on-period comparisons. These measures also improve the ability of management and investors to assess and compare the financial performance and position of Polestar with those of other companies.

These non-GAAP measures are presented for supplemental information purposes only and should not be considered a substitute for financial information presented in accordance with GAAP. The measures are not presented under a comprehensive set of accounting rules and, therefore, should only be read in conjunction with financial information reported under GAAP when assessing Polestar’s operating performance.

The measures may not be the same as similarly titled measures used by other companies due to possible differences in calculation methods and items or events being adjusted. A reconciliation between non-GAAP financial measures and the most comparable GAAP performance measures is provided below.

Non-GAAP financial measures used by management are Adjusted EBITDA, Free Cash Flow, Adjusted Gross Profit / (Loss) and Adjusted Gross Margin.

Adjusted EBITDA is calculated as net loss, adjusted to exclude:

  • Fair value change – Earn-out rights and Class C Shares;

  • Finance expense;

  • Finance income;

  • Foreign exchange gains (losses) on financial activities, net;

  • Income tax benefit (expense);

  • Depreciation and amortization1;

  • Impairment of property, plant and equipment, vehicles under operating leases, and intangibles assets, net of reversals;

  • Gains (losses) on disposals of investments2;

  • Restructuring costs3; and

  • Unusual other operating income and expenses that are considered rare or discrete events and are infrequent in nature.

1 – Depreciation and amortization includes (a) depreciation and amortization capitalized into the carrying value of inventory sold (i.e., part of inventory costs) and (b) depreciation and amortization expense.

2 – Disposals of investments include disposals, by sales or otherwise, of: (a) debt or equity financial instruments issued by another entity that are held as investments, (b) intangible assets, (c) property, plant, and equipment, and (d) groups of assets and liabilities representing disposal groups that were transferred together as part of individual transactions.

3 – Restructuring costs include expenses associated with programs that were planned and controlled by management, and materially changed either (a) the scope of a business undertaken by the Group or (b) the manner in which business is conducted.

Management reviews this measure and believes it provides meaningful insight into the core business’s underlying operating performance and trends, before the effect of any adjusting items.

Free Cash Flow

Free Cash Flow is calculated as cash used for operating activities plus cash used to acquire property, plant and equipment and intangible assets. This measure is reviewed by management and management considers it to be a relevant measure for assessing cash generated by operating activities that are available to repay debts and spend on other strategic initiatives.

Adjusted Gross Profit / (Loss) and Adjusted Gross Margin

Adjusted Gross Profit / (Loss) is calculated as gross profit / (loss), adjusted to exclude: (i) expenses arising from the impairment of property, plant and equipment, vehicles under operating leases, and intangible assets; and (ii) unusual other items of income or expense that are considered rare or discrete events and are infrequent in nature. Adjusted Gross Margin is calculated as Adjusted Gross Profit / (Loss) divided by revenue. These measures are reviewed by management and management considers them to be useful measures for assessing Polestar’s historical operating performance as they facilitate comparison between periods by excluding the non-cash impairment expense, the measurement of which includes significant assumptions related to future periods, and other items which are considered rare or discrete.

Unaudited reconciliation of Non-GAAP measures

Adjusted EBITDA

 

(in millions of U.S. dollars)

For the three months ended March 31,

 

2026

 

2025

 

Adjusted EBITDA

 

 

Net loss

(383

)

(166

)

Fair value change – Earn-out rights and Class C shares

(3

)

(11

)

Finance expense1

99

 

93

 

Finance income1

(3

)

(6

)

Foreign exchange losses / (gains) on financial activities, net1

13

 

(31

)

Income tax expense / (benefit)

11

 

(1

)

Depreciation and amortization

33

 

31

 

Impairment reversals

(1

)

 

Restructuring costs

(1

)

 

Unusual other operating income and expense, net

 

(5

)

Adjusted EBITDA

(235

)

(96

)

1 – Some values for the period ended March 31, 2025 were re-presented.

(in millions of U.S. dollars)

For the three months ended March 31,

 

2026

 

2025

Adjusted Gross Profit / (Loss)

 

 

Gross (Loss) / Profit

(20

)

65

Impairment reversals

(1

)

Adjusted Gross Profit / (Loss)

(21

)

65

(in millions of U.S. dollars)

For the three months ended March 31,

 

2026

 

2025

 

Adjusted Gross Margin

 

 

Adjusted Gross Profit / (Loss) (a)

(21

)

65

 

Revenue (b)

633

 

632

 

Adjusted Gross Margin (a/b)

(3.3

)%

10.3

%

 

Anna Gavrilova

Head of Investor Relations

[email protected]

Theo Kjellberg

Head of Corporate Communications

[email protected]

KEYWORDS: Sweden Europe

INDUSTRY KEYWORDS: Alternative Vehicles/Fuels Automotive Manufacturing Manufacturing General Automotive Automotive

MEDIA:

Photo
Photo
Logo
Logo

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed

dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK –

– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –

– Completed enrollment in REMBRANDT; Topline data from RUBENS Phase 3 expected by year-end 2026 –

– Presented new analyses of Phase 3 BROOKLYN and BROADWAY studies at the American College of Cardiology Annual Scientific Session (ACC) and simultaneously published in the American Journal of Preventative Cardiology–

– $707.3
million in cash, cash equivalents and marketable securities at March 31, 2026 –

– Management to host PREVAIL update call today at 8:00 AM ET –

NAARDEN, the Netherlands and MIAMI, May 07, 2026 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the quarter ended March 31, 2026 and provided a corporate update.

“Our clinical execution remains strong. We have completed enrollment in REMBRANDT and continue to advance PREVAIL and RUBENS — three Phase 3 trials that underscore the breadth and maturity of our development program,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. “We are excited following an initial blinded review of PREVAIL data after the two-year anniversary of enrollment completion — which showed a Year 1 overall MACE event rate consistent with BROADWAY and a Year 1-to-Year 2 overall MACE event rate lower than expected — and we have decided to conduct an interim analysis in the fourth quarter of 2026. This timing coincides with the minimum 2.5-year follow-up for the trial. We are optimistic about the interim analysis and expect to report the result of the analysis in the first quarter of 2027. Should the trial not stop for efficacy at that time, we anticipate completion by the end of 2027. We will provide further details at our annual Investor Day on August 5, 2026.”

Clinical Development Updates

NewAmsterdam is developing obicetrapib, an oral, low-dose and once-daily, highly-selective cholesteryl ester transfer protein (“CETP”) inhibitor, as a monotherapy and in fixed-dose combination with ezetimibe, as the preferred LDL-C lowering therapy to be used in patients at risk of CVD for whom existing therapies are not sufficiently effective or well-tolerated.

In March 2026, NewAmsterdam presented results from additional analyses of its pivotal Phase 3 BROADWAY and BROOKLYN trials evaluating obicetrapib in patients with established atherosclerotic cardiovascular disease (“ASCVD”) and/or heterozygous familial hypercholesterolemia (“HeFH”) at ACC, which were simultaneously published in the American Journal of Preventative Cardiology. The new analyses explored the potential effects of obicetrapib beyond LDL-C lowering, including signals related to new-onset diabetes mellitus and kidney function, and further evaluated the investigational therapy’s safety profile. Data presented include:

  • Pooled analysis of the BROADWAY and BROOKLYN trials showed that CETP inhibition with obicetrapib 10 mg was associated with a slower annualized decline in estimated glomerular filtration rate (eGFR) (-0.41 vs. -1.08 with placebo; difference of 0.67 mL/min/1.73 m²) in patients with high cardiovascular risk.
  • Patients treated with obicetrapib had nominally fewer composite renal events over 12 months, consisting of death due to cardiovascular or renal causes, eGFR <15 mL/min/1.73 m² post- baseline, ≥40 % decline in eGFR from baseline, kidney transplant, or dialysis initiation. The analysis of time weighted achieved HDL-C versus renal event indicated a strong association between higher achieved HDL-C and lower renal event risk (spline nominal P < 0.0001), independent of baseline HDL-C and eGFR.
  • Pooled Phase 3 safety analysis from BROOKLYN and BROADWAY continued to reinforce the safety and tolerability profile of obicetrapib.
  • Findings that higher small/medium LDL particle (“LDL-P”) discordance was observed to be independently associated with incident major adverse cardiovascular events (“MACE”), specifically in patients with high cardiometabolic burden.

Datasets from the analyses were published in the American Journal of Preventive Cardiology. The full posters presented at ACC are available on the Scientific Publications and Presentations page of the NewAmsterdam Pharma website at www.newamsterdampharma.com/publications/.

NewAmsterdam plans to present additional analyses from the BROOKLYN and BROADWAY studies throughout 2026.

Upcoming Milestones and Ongoing Trials:

Following the successful completion and positive topline results of the Phase 3 BROADWAY, TANDEM, and BROOKLYN trials, NewAmsterdam plans to announce additional clinical data from these trials relating to obicetrapib and the fixed-dose combination (“FDC”) of obicetrapib plus ezetimibe during 2026.

The following Phase 3 trials are currently ongoing:

  • PREVAIL Phase 3 trial: PREVAIL is a cardiovascular outcomes trial (“CVOT”) evaluating obicetrapib in patients with a history of ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-lowering therapy. NewAmsterdam completed enrollment of over 9,500 patients in April 2024.

  • REMBRANDT Phase 3 trial: The REMBRANDT trial utilizes coronary computed tomography angiography imaging to evaluate the effect of obicetrapib plus ezetimibe FDC on coronary plaque burden. The placebo-controlled, double-blind, randomized, Phase 3 trial is being conducted in adult participants with high-risk ASCVD with evidence of coronary plaque who are not adequately controlled by their maximally tolerated lipid-modifying therapy, with the aim to assess the impact of the obicetrapib 10 mg plus ezetimibe 10 mg FDC daily on lipid-rich coronary plaque and arterial wall inflammation characteristics. In March 2026, the trial completed enrollment of 323 patients.

  • RUBENS Phase 3 trial: Initiated in December 2025, the RUBENS trial is evaluating obicetrapib alone or in combination with ezetimibe in patients with type 2 diabetes or metabolic syndrome that require additional lowering of LDL-C despite treatment with available therapy. The trial is expected to enroll approximately 300 patients, with topline data expected by year end 2026.

Additionally, NewAmsterdam expects to initiate a new clinical trial evaluating obicetrapib for the prevention of early Alzheimer’s disease in 2026.

First Quarter Financial Results

  • Cash Position: As of March 31, 2026, NewAmsterdam recorded cash, cash equivalents and marketable securities of $707.3 million, compared to $728.9 million as of December 31, 2025. The increase/decrease was primarily driven by cash outflows related to research and development costs as the Company continues development of obicetrapib and spending on selling, general and administrative expenses to support the Company’s ongoing operations, partially offset by cash inflows from the exercise of options and warrants.

  • Revenue: NewAmsterdam recognized $3.0 million in revenue for the quarter ended March 31, 2026, compared to $3.0 million in the same period in 2025. Revenue for the three months ended March 31, 2025 was due to recognition of deferred revenue related to the R&D performance obligation under the Company’s license agreement with the Menarini Group. Revenue for the three months ended March 31, 2026 was related to the Company’s supply agreement with Menarini.

  • Research and Development (“R&D”) Expenses: R&D expenses were $38.0 million in the quarter ended March 31, 2026, compared to $44.8 million for the same period in 2025. This decrease was primarily due to decreases in clinical expenses driven by the completion of Phase 3 clinical trials in the first half of 2025 and non-clinical expenses, partially offset by increases in personnel and manufacturing expenses. Share-based payment expenses included within R&D expenses totaled $6.8 million in the quarter ended March 31, 2026, compared to $5.2 million in the same period in 2025.

  • Selling, General and Administrative (“SG&A”) Expenses: SG&A expenses were $23.5 million in the quarter ended March 31, 2026, compared to $27.2 million for the same period in 2025. This decrease was primarily due to decreases in marketing and communication, legal and intellectual property expenses, partially offset by an increase in personnel expenses. Share-based payment expenses included within SG&A expenses totaled $11.2 million in the quarter ended March 31, 2026, compared to $10.0 million in the same period in 2025.

  • Net loss: Net loss for the quarter ended March 31, 2026, was $48.4 million, compared to net loss of $39.5 million for the same period in 2025. The individual components of the change are described above in addition to interest income, a non-cash gain related to changes in the fair value of our derivative warrant liabilities and foreign exchange losses.

Conference Call and Webcast Information

NewAmsterdam will host a live webcast and conference call at 8:00 a.m. ET today. To access the live call, participants may register here. The live webcast will be available under the “Events” section of the Investor Relations page of the NewAmsterdam website at ir.newamsterdampharma.com.

While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archived replay of the webcast will be available on NewAmsterdam’s website.

About Obicetrapib

Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About Cardiovascular Disease

Cardiovascular disease remains the leading cause of death globally, despite the availability of lipid-lowering therapies (“LLTs”). By 2050 more than 184 million U.S. adults are expected to be affected by CVD and hypertension, including 27 million with coronary heart disease and 19 million with stroke. In the United States from 2019 through 2022, CVD age-adjusted mortality rates increased by 9%, reversing the trend observed since 2010 and undoing nearly a decade of progress. Despite the availability of high-intensity statins and non-statin LLTs, LDL-C target level attainment remains low, contributing to residual cardiovascular risk, and underscoring a significant clinical need for improved therapeutic regimens. Even with 269 million LLT prescriptions written over the last 12 months, 30 million under-treated US adults are not at their risk-based LDL-C goal, of which 13 million have ASCVD. Less than 1 in 4 patients with ASCVD achieve an LDL-C goal of less than 70 mg/dL and only 10% of very high risk ASCVD patients achieve the goal below 55 mg/dL. In addition to the 30 million under-treated U.S. adults, there are 10 million patients diagnosed with elevated LDL-C who are not taking any LLTs including statins. Beyond LDL-C, additional factors are at play, such as lifestyle choices, tobacco use, and obesity, as well as inflammation, thrombosis, triglyceride levels, elevated Lp(a) levels, and type 2 diabetes.

Alzheimer’s Analysis

In BROADWAY, a pre-specified analysis was designed to assess plasma biomarkers of Alzheimer’s disease (“AD”) in patients enrolled in the BROADWAY trial and evaluated the effects of longer duration of therapy (12 months) with a prespecified ApoE population, based on phenotypic analysis. The analysis included 1,535 patients, including 367 ApoE4 carriers (ApoE3/E4 or ApoE4/E4), whose ApoE status was able to be determined. Because this analysis was based on a subset of patients from BROADWAY (which was designed to evaluate LDL-C reductions in an ASCVD and/or HeFH population), the AD analysis was not controlled for baseline differences between the treatment and placebo populations, but statistical analyses were adjusted for baseline biomarker values and age. The absolute and percent change over 12 months in p-tau217, a key biomarker of AD pathology, were measured among patients with baseline and end of study datapoints above the lower limit of quantitation. Additional outcome measures included NFL, GFAP, p-tau181, and Aβ42/40 ratio absolute and percent change over 12 months. NewAmsterdam observed statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full analysis set (p=0.002; n= 1,535) and in ApoE4 carriers (p=0.02; n=367) as well as favorable trends in the other AD biomarkers. Although a safety analysis was not performed in the AD analysis population, in BROADWAY obicetrapib was observed to be well-tolerated, with safety results comparable to placebo.

About NewAmsterdam

NewAmsterdam (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and are subject to the “safe harbor” provisions created thereunder. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” “expects” and variations of these words or similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements relating to: expectations regarding the timing of potential approval decisions from the EMA, UK and Switzerland regulators with respect to MAAs for obicetrapib and the FDC of obicetrapib plus ezetimibe, as well as the potential launch by Menarini in Germany and the United Kingdom; the Company’s intention to conduct the PREVAIL interim analysis; the Company’s expectations regarding the timing of the interim analysis, when the result of the interim analysis may be announced and the potential of PREVAIL being stopped early for efficacy as a result of the interim analysis; the Company’s expectation regarding the timing of the completion of the PREVAIL trial if it is not stopped for efficacy following the interim analysis; expectations for total enrollment figures for and topline data from the RUBENS trial by year-end 2026; the initiation of a new clinical trial evaluating obicetrapib in early Alzheimer’s disease in 2026; the therapeutic potential of the Company’s product candidates; the Company’s other plans regarding and the timing for commencing trials, enrolling patients and completing trials, and the timing and forums for announcing data; expected milestones and anticipated progress toward such milestones; the Company’s anticipated update regarding the PREVAIL trial at its Investor Day; and other statements regarding the Company’s future operations, prospects, objectives, strategies and other future events.

The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon management’s current expectations and assumptions. Actual results or events could differ materially and adversely from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various risks, uncertainties and other factors, including, among others: uncertainties and delays regarding the initiation, enrollment and completion of the Company’s clinical trials; uncertainties regarding the result of the PREVAIL interim analysis; risk that the trends observed in the blinded data in PREVAIL are not being driven by a treatment effect of obicetrapib; the potential for unknown or unadjudicated events to impact the trends observed in the preliminary blinded data in PREVAIL; uncertainties regarding the outcome of the Company’s clinical trials, and whether such outcomes will be adequate to support regulatory review and approval of its product candidates; whether topline, initial or preliminary results, trends or analyses from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials and analyses will be indicative of the results of later clinical trials and analyses, or whether projections regarding clinical outcomes will reflect actual results in future clinical trials or clinical use of the Company’s product candidates; the potential for varying interpretation of the results of clinical trials and analyses; risks related to the Company’s ability to achieve its business plans, objectives and milestones, including approval of the Company’s product candidates and potential commercialization; challenges inherent to the launch of new drug products, if approved; risks related to the Company’s reliance on third parties; unanticipated costs and expenses impacting the Company’s cash runway; the Company’s ability to continue to source the raw materials for its product candidates and ensure adequate supply of product for clinical trials and, if approved, commercialization; the impact of competing product candidates on the Company’s business; risks and uncertainties relating to intellectual property and regulatory exclusivities; changes in domestic and foreign business, market, financial, political, and legal conditions; and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 18, 2026 and in its most recent Quarterly Report Form 10-Q, as well as in other filings the Company may make with the SEC in the future, which are available at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Company Contact

Matthew Philippe
P: 1-917-882-7512
[email protected]

Media Contact

Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
[email protected]

Investor Contact

Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
[email protected]

NewAmsterdam Pharma Company N.V.

Condensed Consolidated Balance Sheet

(Unaudited)
           
  March 31,

2026
    December 31,

2025
 
(In thousands of USD)          
Assets  
Current assets:          
Cash and cash equivalents   457,607       490,002  
Prepayments and other receivables   20,603       38,138  
Marketable securities, current   178,498       146,239  
Restricted cash   1,336       1,321  
Total current assets   658,044       675,700  
Marketable securities, net of current portion   71,239       92,609  
Property, plant and equipment, net   379       383  
Operating right of use asset   21       185  
Intangible assets   375       407  
Long term prepaid expenses   2,585        
Total assets   732,643       769,284  
Liabilities and Shareholders’ Equity          
Current liabilities:          
Accounts payable   8,090       8,970  
Accrued expenses and other current liabilities   5,092       15,422  
Deferred revenue, current   3,987       3,987  
Lease liability, current   23       136  
Derivative warrant liabilities   50,229       57,272  
Total current liabilities   67,421       85,787  
Lease liability, net of current portion         66  
Total liabilities   67,421       85,853  
Commitments and contingencies (Note 12)          
Shareholders’ Equity:          
Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 116,641,656
and 114,399,326 shares issued and outstanding at March 31, 2026 and
December 31, 2025 respectively
  14,594       14,278  
Additional paid-in capital   1,457,238       1,426,750  
Accumulated loss   (810,831 )     (762,390 )
Accumulated other comprehensive income   4,221       4,793  
Total shareholders’ equity   665,222       683,431  
Total liabilities and shareholders’ equity   732,643       769,284  
NewAmsterdam Pharma Company N.V.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)
     
  For the three months ended March 31,  
  2026     2025  
(In thousands of USD, except per share amounts)          
Revenue   3,040       2,978  
Operating expenses:          
Research and development expenses   38,009       44,751  
Selling, general and administrative expenses   23,451       27,152  
Total operating expenses   61,460       71,903  
Operating loss   (58,420 )     (68,925 )
Other income (expense):          
Interest income   5,650       7,351  
Fair value change – earnout         3,992  
Fair value change – warrants   5,942       13,762  
Foreign exchange gains/(losses)   (1,613 )     4,293  
Loss before tax   (48,441 )     (39,527 )
Income tax expense          
Loss for the year   (48,441 )     (39,527 )
Other comprehensive income/(loss)          
Unrealized gain/(loss) on available-for-sale securities, net of tax   (572 )     (33 )
Total comprehensive loss for the year, net of tax   (49,013 )     (39,560 )
NewAmsterdam Pharma Company N.V.

Condensed Consolidated Statements of Shareholders’ Equity

(Unaudited)
                                   
(In thousands of USD, except share amounts) Shares     Amount     Additional
Paid-In Capital
    Accumulated
Loss
    Accumulated
Other
Comprehensive
Income
    Total
Shareholders’
Equity
 
Balance at December 31, 2024   108,064,340       13,444       1,298,160       (558,571 )     4,467       757,500  
Issuance of Earnout Shares   1,743,136       226       40,581                   40,807  
Exercise of Pre-Funded Warrants   1,293,938       162       (162 )                  
Exercise of warrants   15,942       2       410                   412  
Exercise of stock options   909,140       116       2,875                   2,991  
Vesting of RSUs   142,795       18       (18 )                  
Share-based compensation               15,213                   15,213  
Total loss and comprehensive loss for the period                     (39,527 )     (33 )     (39,560 )
As at March 31, 2025   112,169,291       13,968       1,357,059       (598,098 )     4,434       777,363  
                                   
Balance at December 31, 2025   114,399,326       14,278       1,426,750       (762,390 )     4,793       683,431  
Exercise of warrants   56,619       8       1,745                   1,753  
Exercise of stock options   1,971,548       278       10,771                   11,049  
Vesting of RSUs   214,163       30       (30 )                  
Share-based compensation               18,002                   18,002  
Total loss and comprehensive loss for the period                     (48,441 )     (572 )     (49,013 )
As at March 31, 2026   116,641,656       14,594       1,457,238       (810,831 )     4,221       665,222  
NewAmsterdam Pharma Company N.V.

Condensed Consolidated Statements of Cash Flows

(Unaudited)
     
  For the three months ended March 31,  
  2026     2025  
(In thousands of USD)          
Operating activities:          
Loss for the period   (48,441 )     (39,527 )
Non-cash adjustments to reconcile loss for the period to net cash flows:          
Depreciation and amortization   62       52  
Non-cash rent expense   (16 )     3  
Fair value change – derivative earnout and warrants   (5,942 )     (17,754 )
Loss on disposal of property, plant and equipment   12        
Foreign exchange (gains)/losses   1,613       (4,293 )
Amortization of premium/discount on available-for-sale debt securities   10       (513 )
Share-based compensation   18,002       15,213  
Changes in working capital:          
Changes in prepayments and other receivables   15,219       16,031  
Changes in accounts payable   (793 )     2,251  
Changes in accrued expenses and other current liabilities   (10,330 )     (4,953 )
Changes in deferred revenue         (2,978 )
Net cash used in operating activities   (30,604 )     (36,468 )
Investing activities:          
Purchase of property, plant and equipment, including internal use software   (38 )     (16 )
Maturities of marketable securities   51,000       12,500  
Purchases of marketable securities   (62,471 )     (9,629 )
Net cash (used in)/provided by investing activities   (11,509 )     2,855  
Financing activities:          
Transaction costs on December 2024 issue of Ordinary Shares and Pre-Funded Warrants         (1,586 )
Proceeds from exercise of warrants   651       183  
Proceeds from exercise of options   10,414       7,922  
Net cash provided by financing activities   11,065       6,519  
Net change in cash, cash equivalents and restricted cash   (31,048 )     (27,094 )
Foreign exchange differences   (1,332 )     3,771  
Cash, cash equivalents and restricted cash at the beginning of the period   491,323       771,743  
Cash, cash equivalents and restricted cash at the end of the period   458,943       748,420  
Noncash financing and investing activities          
Issuance of earnout shares         40,807  
           
Reconciliation of cash, cash equivalents and restricted cash to the Condensed Consolidated Balance Sheets          
Cash and cash equivalents   457,607       748,420  
Restricted cash   1,336        
    458,943       748,420  



Optimum Reports First Quarter 2026 Results

Optimum Reports First Quarter 2026 Results

NEW YORK–(BUSINESS WIRE)–
Optimum Communications, Inc. (NYSE: OPTU) today reports results for the first quarter ended March 31, 2026.

Dennis Mathew, Optimum Chairman and Chief Executive Officer, said: “The first quarter reflects the deliberate choices we are making to build a more resilient business over time. We continued to navigate an intense competitive environment with strategic focus, executing against our core priorities of strengthening broadband trends, maintaining financial discipline, and investing for long-term value creation. These efforts contributed to year-over-year margin expansion, underscoring our focus on operating efficiency and disciplined execution. In doing so, we took meaningful steps toward simplifying how we go to market, improving the quality of our subscriber base and advancing our convergence strategy to drive more consistent returns. We were encouraged by strong momentum in mobile, which delivered its strongest quarter in six years with 52k net additions, reinforcing our conviction in multi-product relationships, with growth increasingly driven by customers with stronger engagement, supporting lower churn and improved lifetime value. We believe these actions, alongside our ongoing work to evolve our capital structure, are the right foundation for creating durable long-term value for our customers, our employees, and our shareholders.”

First Quarter 2026 Overview

  • Total revenue of $2.07 billion in Q1 2026 (-4.0% year over year)
  • Residential revenue of $1.56 billion in Q1 2026 (-6.5% year over year)
    • Residential average revenue per user (ARPU)(1) $132.32 (-1.2% year over year)

    • Convergence ARPU(2) $79.32 (+1.2% year over year)

  • Net loss attributable to stockholders of ($2,884.1) million (($6.10)/share on a diluted basis) in Q1 2026, includes a non-cash impairment charge of $2.7 billion related to our indefinite-lived cable franchise rights, compared to ($75.7) million(($0.16)/share on a diluted basis) in Q1 2025
  • Net cash flows from operating activities of $170.3 million (-9.2% year over year) in Q1 2026
  • Adjusted EBITDA(3) of $789.0 million (-1.3% year over year), margin of 38.2% in Q1 2026
  • Cash capital expenditures of $307.7 million (-13.6% year over year), capital intensity(4)of 14.9%in Q1 2026
  • Free Cash Flow (deficit)(3) of ($137.4) million in Q1 2026 compared to ($168.6) million in Q1 2025

First Quarter 2026 Key Operational Highlights

  • Advancing Broadband Strategy Amid Competitive Market; Net Losses of 64k
    • Total broadband primary service units (PSUs) net losses of -64kin Q1 2026(5), which includes an adjustment related to prior periods of 8k, compared to -37k in Q1 2025, ending total broadband subscribers of 4.1 million

    • Advancing a simplified go-to-market approach and proactive base management initiatives to improve sales momentum, customer lifetime value and reduce churn

    • Residential broadband customer base continues to move to higher speed tiers, with 47% of the base taking 1 Gig or higher speeds at the end of Q1 2026, which grew in the last 3 years from 21% in Q1 2023

  • Best Mobile Line Net Add Performance in 6 Years, with +52k Line Net Additions in Q1 2026
    • Mobile line net additions of +52k in Q1 2026, representing the strongest quarterly performance in six years, bringing total mobile lines to 674k

    • Residential mobile service revenue grew 35% year over year to $50 million in Q1 2026, compared to $37 million in Q1 2025

    • Residential mobile penetration of the broadband base(6) reached 8.8% at end of Q1 2026, compared to 6.3% in Q1 2025

  • Improved Video Margin and Churn Supported by Adoption of New Tiered Offerings
    • New tiered video packages, Entertainment TV, Extra TV, and Everything TV reached 17% penetration of the residential video base at the end of Q1 2026, up from 6% in Q1 2025

    • Continued migration from legacy video packages to new tiered offerings improves retention and strengthens video margin profile

    • Video gross margin in Q1 2026 expanded by approximately 1,000 basis points in the last three years compared to Q1 2023

    • Annualized video churn improved by approximately 690 basis points year over year in Q1 2026

    • Residential video ARPU(7) grew +3.7% year-over-year, partially offsetting video volume declines in revenue

  • Driving Margin Expansion Through Cost Discipline and Efficiency
    • Gross margin of 69.4% in Q1 2026 expanded by 60 basis points year over year

    • Adjusted EBITDA(3) margin of 38.2% in Q1 2026 expanded by 110 basis points year over year, reflecting cost discipline

    • Efficiency gains were driven by workforce productivity initiatives, lower truck rolls, and increased use of AI-enabled tools and automation

  • Expanding and Enhancing Our Networks
    • Added +38k total new passings in Q1 2026 and +190k total new passings in the last twelve months (LTM)

    • At the end of Q1 2026, approximately 96% of the total footprint had 1 Gig or higher speeds available

    • Lightpath expansion continues to progress, with capital being deployed to support the previously announced $362 million of total contract value of AI-driven awards

Balance Sheet Review as of March 31, 2026

  • Consolidated net debt(8) for Optimum Communications was $25,488 million, representing consolidated net leverage of 7.5x L2QA(9)
    • The weighted average cost of debt for consolidated Optimum Communications was 6.8% and the weighted average life of debt was 3.1 years

  • Net debt(8) for CSC Holdings, LLC Restricted Group was $21,200 million, representing net leverage of 20.3x L2QA(9)
    • The weighted average cost of debt for CSC Holdings, LLC Restricted Group was 6.6% and the weighted average life of debt was 3.0 years

  • Consolidated net debt(8) for Cablevision Litchfield, LLC and CSC Optimum Holdings, LLC (the “UnSub Group”) was $2,751 million, representing consolidated net leverage of 1.4x L2QA(9)
    • The weighted average cost of debt for the UnSub Group was 9.0% and the weighted average life of debt was 2.7 years

  • Consolidated net debt(8) for Lightpath was $1,560 million, representing net leverage of 4.8x L2QA(9)
    • The weighted average cost of debt for Lightpath Consolidated was 5.6% and the weighted average life of debt was 4.9 years

Shares Outstanding

  • As of March 31, 2026, Optimum Communications had 476,283,057 combined shares of Class A and Class B common stock outstanding

Recent Refinancing Activity

  • On March 3, 2026, Cablevision Lightpath LLC (“Lightpath”), through its wholly owned and bankruptcy-remote indirect subsidiary Lightpath Fiber Issuer LLC, refinanced all of its outstanding indebtedness through an asset-backed securitization transaction. In connection with the refinancing, Lightpath repaid in full and terminated all prior debt facilities, including its senior notes due 2028, senior secured notes due 2027 and its term loan facility balance previously outstanding.

  • On January 12, 2026, Cablevision Litchfield, LLC (“Cablevision Litchfield”) and CSC Optimum Holdings, LLC (“CSC Optimum”), each indirect wholly-owned subsidiaries of Optimum Communications, entered into an amended and restated credit agreement, providing for an incremental term loan commitment in an aggregate principal amount of $1.1 billion. This loan commitment has the same terms as the initial term loans extended pursuant to the credit agreement with JPMorgan Chase Bank, N.A. (entered into in November 2025) including maturity, interest rate and amortization. The proceeds from the loans made pursuant to the incremental term loan commitment were used to refinance all of the outstanding debt under a receivables facility loan and security agreement (entered into in July 2025) and pay certain fees and expenses relating to the foregoing, with any remaining proceeds being used for general corporate purposes.

Customer Metrics (in thousands, except per customer amounts)

 

Q1-24

Q2-24

Q3-24(10)

Q4-24(11)

FY-24(11)

Q1-25

Q2-25

Q3-25

Q4-25

FY-25

Q1-26(5)

Total Passings(12)

9,679.3

9,746.4

9,784.7

9,830.8

9,830.8

9,856.1

9,891.5

9,942.9

10,008.2

10,008.2

10,045.9

Total Passings additions

50.6

67.2

38.3

54.4

210.4

25.2

35.4

51.4

65.2

177.3

37.8

Total Customer Relationships(13)(14)

 

 

 

 

 

 

 

 

 

 

 

Residential

4,326.8

4,272.3

4,217.5

4,173.7

4,173.7

4,130.5

4,088.0

4,028.6

3,963.8

3,963.8

3,897.0

SMB

379.7

379.7

378.4

376.6

376.6

375.3

374.3

371.9

369.9

369.9

367.1

Total Unique Customer Relationships

4,706.5

4,652.0

4,595.9

4,550.3

4,550.3

4,505.9

4,462.2

4,400.5

4,333.6

4,333.6

4,264.1

Residential net additions (losses)

(36.3)

(54.5)

(54.8)

(41.8)

(187.4)

(43.2)

(42.5)

(59.3)

(64.9)

(209.9)

(66.8)

Business Services net additions (losses)

(0.7)

0.0

(1.2)

(1.8)

(3.7)

(1.3)

(1.1)

(2.4)

(2.0)

(6.7)

(2.8)

Total customer net additions (losses)

(37.0)

(54.5)

(56.1)

(43.6)

(191.1)

(44.4)

(43.6)

(61.7)

(66.9)

(216.6)

(69.5)

Residential PSUs

 

 

 

 

 

 

 

 

 

 

 

Broadband

4,139.7

4,088.7

4,039.5

3,999.9

3,999.9

3,963.3

3,928.3

3,872.2

3,811.4

3,811.4

3,749.6

Video

2,094.7

2,021.9

1,944.8

1,880.1

1,880.1

1,792.4

1,736.3

1,674.9

1,628.4

1,628.4

1,570.7

Telephony

1,452.1

1,391.1

1,326.0

1,269.2

1,269.2

1,200.0

1,147.8

1,093.1

1,041.6

1,041.6

994.9

Broadband net additions (losses)

(29.4)

(51.0)

(49.2)

(37.7)

(167.3)

(36.6)

(35.0)

(56.2)

(60.7)

(188.4)

(61.9)

Video net additions (losses)

(77.7)

(72.8)

(77.0)

(64.3)

(291.8)

(87.7)

(56.1)

(61.4)

(46.5)

(251.7)

(57.7)

Telephony net additions (losses)

(63.1)

(61.1)

(65.1)

(56.7)

(246.0)

(69.2)

(52.2)

(54.7)

(51.5)

(227.7)

(46.7)

Residential ARPU(1) ($)

135.67

135.95

135.77

133.95

135.44

133.93

133.68

133.28

134.49

134.18

132.32

Convergence ARPU(2) ($)

75.57

76.36

77.43

77.47

76.77

78.38

77.95

78.26

80.87

79.09

79.32

SMB PSUs

 

 

 

 

 

 

 

 

 

 

 

Broadband

348.5

348.8

347.7

346.1

346.1

345.7

345.6

343.6

342.0

342.0

339.7

Video

87.3

85.4

83.3

81.0

81.0

78.7

76.6

74.6

72.6

72.6

70.4

Telephony

200.7

199.2

196.8

194.5

194.5

191.9

188.9

185.6

182.5

182.5

179.2

Broadband net additions (losses)

(0.4)

0.3

(1.1)

(1.6)

(2.8)

(0.4)

(0.1)

(2.1)

(1.5)

(4.1)

(2.3)

Video net additions (losses)

(2.3)

(1.9)

(2.1)

(2.2)

(8.5)

(2.4)

(2.0)

(2.0)

(2.0)

(8.5)

(2.1)

Telephony net additions (losses)

(2.6)

(1.4)

(2.4)

(2.3)

(8.8)

(2.6)

(3.0)

(3.3)

(3.1)

(12.0)

(3.3)

Total Mobile Lines(15)

 

 

 

 

 

 

 

 

 

 

 

Mobile ending lines

351.6

384.5

420.1

459.6

459.6

508.6

546.4

584.4

622.5

622.5

674.1

Mobile line net additions

29.3

33.0

35.5

39.5

137.4

49.0

37.8

38.0

38.1

162.9

51.6

Fiber (FTTH) Customer Metrics (in thousands)

 

Q1-24

Q2-24

Q3-24

Q4-24

FY-24

Q1-25

Q2-25

Q3-25

Q4-25

FY-25

Q1-26

FTTH Total Passings(16)

2,780.0

2,842.0

2,893.7

2,961.8

2,961.8

2,995.0

3,023.4

3,053.0

3,096.0

3,096.0

3,121.6

FTTH Total Passing additions

44.8

62.0

51.7

68.1

226.6

33.2

28.5

29.6

43.0

134.2

25.6

FTTH Residential customer relationships

385.2

422.7

468.5

523.4

523.4

590.2

644.6

683.6

694.8

694.8

706.7

FTTH SMB customer relationships

9.4

11.4

13.1

14.7

14.7

16.5

18.5

19.8

21.2

21.2

22.4

FTTH Total Customer Relationships(17)

394.6

434.1

481.6

538.2

538.2

606.7

663.0

703.5

715.9

715.9

729.1

FTTH Residential net additions

51.4

37.5

45.7

55.0

189.6

66.7

54.4

39.0

11.1

171.3

12.0

FTTH SMB net additions

1.9

2.0

1.7

1.7

7.2

1.8

1.9

1.4

1.3

6.4

1.2

FTTH Total Customer Net Additions

53.2

39.5

47.4

56.6

196.8

68.5

56.3

40.4

12.5

177.8

13.2

Optimum Communications, Inc. Consolidated Operating Results
($ and shares in thousands, except per share data)
(unaudited)
 

 

Three Months Ended March 31,

 

 

2026

 

 

 

2025

 

Revenue:

Broadband

$

850,039

 

 

$

899,561

 

Video

 

602,223

 

 

 

665,568

 

Telephony

 

58,406

 

 

 

66,412

 

Mobile

 

49,549

 

 

 

36,699

 

Residential revenue

 

1,560,217

 

 

 

1,668,240

 

Business services and wholesale

 

364,300

 

 

 

363,545

 

News and Advertising

 

119,674

 

 

 

102,410

 

Other

 

21,177

 

 

 

18,087

 

Total revenue

 

2,065,368

 

 

 

2,152,282

 

Operating expenses:

 

 

 

Programming and other direct costs

 

631,129

 

 

 

670,531

 

Other operating expenses

 

660,203

 

 

 

698,186

 

Restructuring, impairments and other operating items

 

2,727,629

 

 

 

21,622

 

Depreciation and amortization

 

406,496

 

 

 

418,485

 

Operating income

 

(2,360,089

)

 

 

343,458

 

Other income (expense):

 

 

 

Interest expense, net

 

(457,819

)

 

 

(428,016

)

Gain on investments and sale of affiliate interests

 

 

 

 

5

 

Gain (loss) on interest rate swap contracts, net

 

2,398

 

 

 

(1,719

)

Loss on extinguishment of debt and write-off of deferred financing costs

 

(106,045

)

 

 

 

Other expense, net

 

(529

)

 

 

(963

)

Loss before income taxes

 

(2,922,084

)

 

 

(87,235

)

Income tax benefit

 

45,108

 

 

 

15,964

 

Net loss

 

(2,876,976

)

 

 

(71,271

)

Net income attributable to noncontrolling interests

 

(7,095

)

 

 

(4,405

)

Net loss attributable to Optimum Communications stockholders

$

(2,884,071

)

 

$

(75,676

)

Net loss per share:

 

 

 

Basic and diluted net loss per share attributable to Optimum Communications, Inc. stockholder

$

(6.10

)

 

$

(0.16

)

Basic and diluted weighted average common shares (in thousands)

 

472,420

 

 

 

464,862

 

Optimum Communications, Inc. Consolidated Statements of Cash Flows

($ in thousands)

(unaudited)

Three Months Ended March 31,

 

 

2026

 

 

 

2025

 

Cash flows from operating activities:

 

 

 

Net loss

$

(2,876,976

)

 

$

(71,271

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

406,496

 

 

 

418,485

 

Indefinite-lived cable franchise rights impairment

 

2,700,000

 

 

 

 

Gain on investments, sale of assets or sale of affiliate interests

 

 

 

 

(5

)

Loss on extinguishment of debt and write-off of deferred financing costs

 

106,045

 

 

 

 

Amortization of deferred financing costs and discounts (premiums) on indebtedness

 

9,911

 

 

 

3,992

 

Share-based compensation expense

 

14,977

 

 

 

15,449

 

Deferred income taxes

 

(111,441

)

 

 

(127,410

)

Decrease in right-of-use assets

 

10,931

 

 

 

11,150

 

Allowance for credit losses

 

20,628

 

 

 

16,196

 

Other

 

479

 

 

 

399

 

Change in operating assets and liabilities, net of effects of acquisitions and dispositions:

 

 

 

Accounts receivable, trade

 

13,941

 

 

 

17,187

 

Prepaid expenses and other assets

 

(79,588

)

 

 

(55,377

)

Amounts due from and due to affiliates

 

(8,277

)

 

 

13,905

 

Accounts payable and accrued liabilities

 

(29,207

)

 

 

42,958

 

Interest payable

 

(26,611

)

 

 

(120,856

)

Deferred revenue

 

18,043

 

 

 

18,816

 

Interest rate swap contracts

 

932

 

 

 

3,865

 

Net cash provided by operating activities .

 

170,283

 

 

 

187,483

 

Cash flows from investing activities:

 

 

 

Capital expenditures

 

(307,704

)

 

 

(356,124

)

Payments for acquisitions, net of cash acquired

 

 

 

 

(7,616

)

Other, net

 

3,031

 

 

 

191

 

Net cash used in investing activities

 

(304,673

)

 

 

(363,549

)

Cash flows from financing activities:

 

 

 

Proceeds from long-term debt

 

2,756,954

 

 

 

450,000

 

Repayment of debt

 

(2,524,081

)

 

 

(220,014

)

Principal payments on finance lease obligations

 

(6,289

)

 

 

(17,262

)

Additions to deferred financing costs

 

(112,630

)

 

 

 

Other, net

 

(7,929

)

 

 

(13,997

)

Net cash provided by financing activities

 

106,025

 

 

 

198,727

 

Net increase (decrease) in cash and cash equivalents

 

(28,365

)

 

 

22,661

 

Effect of exchange rate changes on cash and cash equivalents

 

17

 

 

 

(54

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

(28,348

)

 

 

22,607

 

Cash, cash equivalents and restricted cash at beginning of year

 

1,141,443

 

 

 

256,824

 

Cash, cash equivalents and restricted cash at end of year

$

1,113,095

 

 

$

279,431

 

Reconciliation of Non-GAAP Financial Measures

We define Adjusted EBITDA, which is a non-GAAP financial measure, as net income (loss) excluding income taxes, non-operating income or expenses, gain (loss) on extinguishment of debt and write-off of deferred financing costs, gain (loss) on interest rate swap contracts, gain (loss) on derivative contracts, gain (loss) on investments and sale of affiliate interests, interest expense, net, depreciation and amortization, share-based compensation, restructuring, impairments and other operating items (such as significant legal settlements and contractual payments for terminated employees). We define Adjusted EBITDA margin as Adjusted EBITDA divided by total revenue.

Adjusted EBITDA eliminates the significant non-cash depreciation and amortization expense that results from the capital-intensive nature of our business and from intangible assets recognized from acquisitions, as well as certain non-cash and other operating items that affect the period-to-period comparability of our operating performance. In addition, Adjusted EBITDA is unaffected by our capital and tax structures and by our investment activities.

We believe Adjusted EBITDA is an appropriate measure for evaluating our operating performance. Adjusted EBITDA and similar measures with similar titles are common performance measures used by investors, analysts and peers to compare performance in our industry. Internally, we use revenue and Adjusted EBITDA measures as important indicators of our business performance and evaluate management’s effectiveness with specific reference to these indicators. We believe Adjusted EBITDA provides management and investors a useful measure for period-to-period comparisons of our core business and operating results by excluding items that are not comparable across reporting periods or that do not otherwise relate to our ongoing operating results. Adjusted EBITDA should be viewed as a supplement to and not a substitute for operating income (loss), net income (loss), and other measures of performance presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Since Adjusted EBITDA is not a measure of performance calculated in accordance with GAAP, this measure may not be comparable to similar measures with similar titles used by other companies.

We also use Free Cash Flow (defined as net cash flows from operating activities less cash capital expenditures) as a liquidity measure. We believe this measure is useful to investors in evaluating our ability to service our debt and make continuing investments with internally generated funds, although it may not be directly comparable to similar measures reported by other companies.

Reconciliation of Net Loss to Adjusted EBITDA

($ in thousands)

(unaudited)

 

 

Three Months Ended March 31,

 

 

2026

 

 

 

2025

 

 

 

 

 

Net loss

$

(2,876,976

)

 

$

(71,271

)

Income tax benefit

 

(45,108

)

 

 

(15,964

)

Other expense, net

 

529

 

 

 

963

 

Loss (gain) on interest rate swap contracts, net

 

(2,398

)

 

 

1,719

 

Gain on investments and sale of affiliate interests

 

 

 

 

(5

)

Loss on extinguishment of debt and write-off of deferred financing costs

 

106,045

 

 

 

 

Interest expense, net

 

457,819

 

 

 

428,016

 

Depreciation and amortization

 

406,496

 

 

 

418,485

 

Restructuring, impairments and other operating items

 

2,727,629

 

 

 

21,622

 

Share-based compensation

 

14,977

 

 

 

15,449

 

Adjusted EBITDA

$

789,013

 

 

$

799,014

 

Adjusted EBITDA margin

 

38.2

%

 

 

37.1

%

Reconciliation of net cash flow from operating activities to Free Cash Flow (Deficit)

(in thousands)

(unaudited):

 

 

Three Months Ended March 31,

 

 

2026

 

 

 

2025

 

 

 

 

 

Net cash flows from operating activities

$

170,283

 

 

$

187,483

 

Less: Capital expenditures (cash)

 

307,704

 

 

 

356,124

 

Free Cash Flow (Deficit)

$

(137,421

)

 

$

(168,641

)

Consolidated Net Debt as of March 31, 2026

($ in millions)

 

CSC Holdings, LLC Restricted Group

Principal Amount

 

Coupon / Margin

 

Maturity

Drawn RCF

$2,125

 

SOFR+2.350%

 

2027

Term Loan B-5

2,820

 

ABR(18)

 

2027

Guaranteed Notes

1,310

 

5.500%

 

2027

Guaranteed Notes

1,000

 

5.375%

 

2028

Guaranteed Notes

1,000

 

11.250%

 

2028

Guaranteed Notes

2,050

 

11.750%

 

2029

Guaranteed Notes

1,750

 

6.500%

 

2029

Guaranteed Notes

1,100

 

4.125%

 

2030

Guaranteed Notes

1,000

 

3.375%

 

2031

Guaranteed Notes

1,500

 

4.500%

 

2031

Senior Notes

1,046

 

7.500%

 

2028

Legacy unexchanged Cequel Notes

4

 

7.500%

 

2028

Senior Notes

2,250

 

5.750%

 

2030

Senior Notes

2,325

 

4.625%

 

2030

Senior Notes

500

 

5.000%

 

2031

CSC Holdings, LLC Restricted Group Gross Debt

21,780

 

 

 

 

CSC Holdings, LLC Restricted Group Cash

(580)

 

 

 

 

CSC Holdings, LLC Restricted Group Net Debt

$21,200

 

 

 

 

 

 

 

 

 

 

CSC Holdings, LLC Restricted Group Undrawn RCF

$149.7

 

 

 

 

UnSub Group Credit Agreement

Principal Amount

 

Coupon / Margin

 

Maturity

Term Loan B-8

$3,100

 

9.000%

 

2028

UnSub Group cash

(349)

 

 

 

 

UnSub Net Debt

$2,751

 

 

 

 

Lightpath Consolidated

Principal Amount

 

Coupon / Margin

 

Maturity

Secured Fiber Network Revenue Note

$1,527

 

5.597%

 

2031

Secured Fiber Network Revenue Note

130

 

5.890%

 

2031

Lightpath Consolidated Gross Debt

1,657

 

 

 

 

Lightpath Consolidated Cash

(97)

 

 

 

 

Lightpath Consolidated Net Debt

$1,560

 

 

 

 

 

 

 

 

 

 

Lightpath Consolidated available and undrawn under Variable Funding Note

$93.9

 

 

 

 

Net Leverage Schedule as of March 31, 2026

($ in millions)

 

 

 

 

 

 

 

 

 

CSC Holdings

Restricted

Group(19)

 

Lightpath

Consolidated(21)

 

UnSub Group

 

Optimum

Communications

Consolidated

 

 

 

 

 

 

 

 

Gross Debt Consolidated(20)

$21,780

 

$1,657

 

$3,100

 

$26,537

Cash

(580)

 

(97)

 

(349)

 

(1,049)

Net Debt Consolidated(8)

$21,200

 

$1,560

 

$2,751

 

$25,488

LTM EBITDA

$1,002

 

$296

 

$2,014

 

$3,326

L2QA EBITDA

$1,042

 

$325

 

$2,009

 

$3,382

Net Leverage (LTM)

21.2x

 

5.3x

 

1.4x

 

7.7x

Net Leverage (L2QA)(9)

20.3x

 

4.8x

 

1.4x

 

7.5x

WACD(%)

6.6%

 

5.6%

 

9.0%

 

6.8%

Reconciliation to Financial Reported Debt

 

 

Optimum

Communications

Consolidated

Total Debenture and Loans from Financial Institutions (Carrying Amount)

$26,339

Unamortized financing costs and discounts, net of unamortized premiums

198

Gross Debt Consolidated(20)

26,537

Finance leases

104

Total Debt

26,641

Cash

(1,049)

Net Debt Including Finance Leases

$25,592

(1)

Residential ARPU is calculated by dividing the average monthly revenue for the respective period derived from the sale of broadband, video, telephony and mobile services to residential customers by the average number of total residential customers for the same period and excludes mobile-only customer relationships.

(2)

Convergence ARPU is calculated by dividing the average monthly revenue for the respective period derived from the sale of broadband and mobile services to residential customers by the average number of total residential broadband customers for the same period and excludes mobile-only customer relationships.

(3)

See “Reconciliation of Non-GAAP Financial Measures” beginning on page 7 of this earnings release.

(4)

Capital intensity refers to total cash capital expenditures as a percentage of total revenue.

(5)

Broadband subscriber net adds video subscriber net adds in Q1-26 include subscriber adjustments taken in the quarter related to prior periods. Excluding these adjustments broadband subscriber net losses would have been 56k and video subscriber net losses would have been 50k.

(6)

Mobile penetration of broadband base is expressed as the percentage of customers subscribing to both broadband and mobile services divided by the total broadband customer base. Excludes mobile only customers.

(7)

Video ARPU is calculated by dividing the average monthly residential video revenue for the respective period by the average number of total residential video customers for the same period.

(8)

Net debt, defined as the principal amount of debt less cash, and excluding finance leases and other notes.

(9)

L2QA leverage is calculated as quarter end net debt consolidated divided by the last two quarters of Adjusted EBITDA annualized.

(10)

Customer metrics as of September 30, 2024 reflect adjustments to align to the Company’s bulk residential subscriber count policy, resulting in an increase of 4.7 thousand residential customer relationships, 3.8 thousand broadband customers and 5.2 thousand video customers. The impact of these adjustments to customer relationships, broadband and video customer net additions was not material for any period presented and as such prior period metrics were not restated.

(11)

Subscriber net additions (losses) and passings additions exclude 8.3 thousand passings, 2.1 thousand customer relationships, 1.9 thousand broadband subscribers and 0.5 thousand video subscribers that were transferred in connection with a small system sale in Q4-24.

(12)

Total passings represents the estimated number of single residence homes, apartments and condominium units passed by the HFC and FTTH network in areas serviceable without further extending the transmission lines. In addition, it includes commercial establishments that have connected to our hybrid-fiber-coaxial (HFC) and fiber-to-the-home (FTTH) network. Broadband services were not available to approximately 26 thousand total passings and telephony services were not available to approximately 460 thousand total passings as of March 31, 2026.

(13)

Total Unique Customer Relationships represent the number of households/businesses that receive at least one of our fixed-line services. Customers represent each customer account (set up and segregated by customer name and address), weighted equally and counted as one customer, regardless of size, revenue generated, or number of boxes, units, or outlets on our HFC and FTTH network. Free accounts are included in the customer counts along with all active accounts, but they are limited to a prescribed group. Most of these accounts are also not entirely free, as they typically generate revenue through pay-per-view or other pay services and certain equipment fees. Free status is not granted to regular customers as a promotion. In counting bulk residential customers, such as an apartment building, we count each subscribing unit within the building as one customer, but do not count the master account for the entire building as a customer. We count a bulk commercial customer, such as a hotel, as one customer, and do not count individual room units at that hotel.

(14)

Total Customer Relationship metrics do not include mobile-only customers.

(15)

Mobile lines represent the number of residential and business customers’ wireless connections, which include mobile phone handsets and other mobile wireless connected devices. An individual customer relationship may have multiple mobile lines. The FY 2025 and Q1 2026 ending lines include approximately 17.6 thousand and 20.9 thousand lines related to business customers, respectively. The service revenue related to these business customers is reflected in “Business services and wholesale” in the table above.

(16)

Represents the estimated number of single residence homes, apartments and condominium units passed by the FTTH network in areas serviceable without further extending the transmission lines. In addition, it includes commercial establishments that have connected to our FTTH network.

(17)

Represents number of households/businesses that receive at least one of our fixed-line services on our FTTH network. FTTH customers represent each customer account (set up and segregated by customer name and address), weighted equally and counted as one customer, regardless of size, revenue generated, or number of boxes, units, or outlets on our FTTH network. Free accounts are included in the customer counts along with all active accounts, but they are limited to a prescribed group. Most of these accounts are also not entirely free, as they typically generate revenue through pay-per view or other pay services and certain equipment fees. Free status is not granted to regular customers as a promotion. In counting bulk residential customers, such as an apartment building, we count each subscribing unit within the building as one customer, but do not count the master account for the entire building as a customer. We count a bulk commercial customer, such as a hotel, as one customer, and do not count individual room units at that hotel.

(18)

Beginning on March 31, 2025, we are required to pay interest on the Incremental Term Loan B-5 at a rate equal to the alternate base rate (“ABR”), plus the applicable margin, where the ABR is the greater of (x) prime rate or (y) the federal funds effective rate plus 50 basis points, and the applicable margin for any ABR loan is 1.50% per annum. Prior to March 31, 2025, we paid interest at a rate equal to Synthetic USD London Interbank Offered Rate plus 2.50% per annum.

(19)

CSC Holdings, LLC Restricted Group excludes the unrestricted subsidiaries, primarily Lightpath Fiber Issuer LLC, Cablevision Funding LLC, Cablevision Litchfield, LLC and CSC Optimum Holdings, LLC, and certain subsidiaries of CSC Holdings designated as “unrestricted subsidiaries” for the purposes of the CSC Holdings silo on November 25, 2025.

(20)

Principal amount of debt excluding finance leases and other notes.

(21)

Amounts represent Lightpath Consolidated, which primarily consists of Lightpath Fiber Issuer LLC, as well as certain network assets between New York City and Ashburn, Virginia.

 

Certain numerical information is presented on a rounded basis. Minor differences in totals and percentage calculations may exist due to rounding.

About Optimum Communications

Optimum Communications, Inc. (NYSE: OPTU) is one of the largest broadband communications and video services providers in the United States, delivering broadband, video, mobile, proprietary content and advertising services to approximately 4.3 million residential and business customers across 21 states through its Optimum brand. We operate Optimum Media, an advanced advertising and data business, which provides audience-based, multiscreen advertising solutions to local, regional and national businesses and advertising clients. We also operate News 12, which is focused on delivering best-in-class hyperlocal news content.

FORWARD-LOOKING STATEMENTS

Certain statements in this earnings release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this earnings release, including, without limitation, those regarding our intentions, beliefs or current expectations concerning, among other things, our future financial condition, liquidity, capital structure and results of operations; our strategy, objectives, prospects and trends, including driving margin expansion; our 2026 priorities, including, among other things: improving broadband trends (including simplifying products and pricing and improving convergence and value-added product sell-in), maintaining financial discipline (including base management, product margin expansion, cost optimization and our AI and automation capabilities) and investing for long-term value creation (including fiber expansion, network upgrades and investment in technology and tools); our capital structure, including our ability to address upcoming maturities, refinancing activities, deleveraging initiatives and transformation plans; our subscriber trends (including broadband, mobile, video and fiber, churn, customer growth, retention, penetration and lifetime value) and competitive dynamics; our go-to-market strategies and pricing and rate management strategies and the anticipated benefits thereof; network enhancements; and future developments in the markets in which we participate or are seeking to participate. These forward-looking statements can be identified by the use of forward-looking terminology, including without limitation the terms “anticipate”, “believe”, “could”, “estimate”, “expect”, “forecast”, “intend”, “may”, “opportunity”, “plan”, “project”, “should”, “target”, “outlook”, or “will” or, in each case, their negative, or other variations or comparable terminology. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. To the extent that statements in this earnings release are not recitations of historical fact, such statements constitute forward-looking statements, which, by definition, involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements including risks referred to in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q. You are cautioned to not place undue reliance on Optimum Communications’ forward-looking statements. Any forward-looking statement speaks only as of the date on which it was made. Optimum Communications specifically disclaims any obligation to publicly update or revise any forward-looking statement, as of any future date.

Investor Relations

John Hsu: +1 917 405 2097 / [email protected]

Sarah Freedman: +1 631 660 8714 / [email protected]

Media Relations

Lisa Anselmo: +1 516 279 9461 / [email protected]

Janet Meahan: +1 516 519 2353 / [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Technology Mobile/Wireless Entertainment Carriers and Services Advertising Telecommunications Communications TV and Radio Internet

MEDIA:

Axsome Therapeutics Recognizes Mental Health Month

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced its support for Mental Health Month alongside the broader mental health advocacy community. In recognition of this year’s More Good Days Together theme, Axsome is sharing resources to support individuals affected by mental health conditions, their families, and the communities around them.

“At Mental Health America, we are proud to have established Mental Health Month in 1949, with the goal of educating the public about mental illness, mental health, and recovery,” said Pierluigi Mancini, PhD, interim president and CEO of Mental Health America (MHA). “Our 2026 campaign, More Good Days, Together, provides tools and resources that meet people where they are, support them as whole people, and acknowledge that ‘good’ is defined by their unique experience and goals. The path may look different for everyone, but we all deserve more good days, together.”

Mental health conditions are highly prevalent in the U.S., with nearly 1 in 4 adults living with a mental illness.1 Major depressive disorder (MDD), one of the most common mental health conditions, is a leading cause of disability worldwide and impacts over 21 million adults in the U.S. alone.1-3 Nearly 90% of people living with depression report difficulty with work, home, or social activities due to their symptoms, underscoring the impact depression can have on day-to-day life.4

Axsome’s mission is to develop and deliver transformative medicines to improve the brain health of millions of individuals affected by central nervous system conditions, including those living with difficult-to-treat mental illness. To help raise awareness and promote action during Mental Health Month, Axsome is highlighting non-profit organizations and resources that provide education, tools, and community support for individuals and families affected by mental health conditions, including:

  • 2026 Mental Health Month Action Guide (https://mhanational.org/2026-mental-health-month-action-guide/) MHA’s work is driven by its commitment to promote mental health as a critical part of overall wellness, including prevention services for all; early identification and intervention for those at risk; and integrated care, services, and support for those who need them, with recovery as the goal. Its 2026 Mental Health Month Action Guide provides access to online activities, articles, printable tools, and practical resources
  • Anxiety and Depression Association of America (ADAA)’s “Find Your Therapist” platform (https://findyourtherapist.adaa.org/) helps connect people with licensed mental health professionals who specialize in treating anxiety, depression, OCD, PTSD, and other related disorders. This aligns with ADAA’s 2026 annual conference theme around “Innovations in Technology Driving Clinical Care and Research in Mood and Anxiety Disorders,” and the organizations commitment to improving live through collaboration, research, education, and innovation.   
  • The National Alliance on Mental Illness (NAMI) New York Chapter (https://naminycmetro.org/), guided by lived experience and evidence-based practices, helps families and individuals affected by mental illness build better lives through education, support, and advocacy. Later this month NAMI-NYC is hosting its annual Mental Health Street Fest, which is the nation’s largest mental health event, being held since 2007: https://www.namiwalks.org/nyc.

If you or someone you know is in crisis, the 988 Suicide & Crisis Lifeline (https://988lifeline.org/) is a free confidential support service available 24 hours a day, 7 days a week across the United States. When people call, text, or chat 988, they will be connected to trained counselors that are part of the existing Lifeline network. These trained counselors will listen, understand how their problems are affecting them, provide support, and connect them to resources if necessary.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investors:

Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
[email protected]

Media:

Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
[email protected]

References:

  1. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. July 2024. https://www.samhsa.gov/data/report/2023-nsduh-annual-national-report
  2. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. 2017.https://www.who.int/publications/i/item/depression-global-health-estimates
  3. National Institute of Mental Health. Major Depression. Accessed February 2026. https://www.nimh.nih.gov/health/statistics/major-depression
  4. Brody DJ, Hughes JP. Depression prevalence in adolescents and adults: United States, August 2021–August 2023. 2025 Apr; (527)1–11. DOI: https://dx.doi.org/10.15620/cdc/174579.



BKV Corporation Reports First Quarter 2026 Financial and Operational Results

BKV Corporation Reports First Quarter 2026 Financial and Operational Results

DENVER–(BUSINESS WIRE)–
BKV Corporation (“BKV” or the “Company”) (NYSE: BKV), today reported financial and operational results for the first quarter of 2026.

First Quarter 2026 Highlights

  • Net income attributable to BKV of $44.1 million or $0.42 per diluted share

  • Adjusted Net Income attributable to BKV of $22.4 million or $0.22 per diluted share

  • Adjusted EBITDAX attributable to BKV of $112.0 million

  • Net cash provided by operating activities of $72.0 million

  • Net cash provided by operating activities before working capital of $109.3 million

  • Accrued capital expenditures of $118.6 million

  • Adjusted Free Cash Flow before Power Growth attributable to BKV of $20.0 million

  • Average net production of 925.0 MMcfe/d

  • Total generation from the Power JV’s Temple plants of 1,981 GWh

  • Barnett Zero quarterly sequestration of approximately 35,800 metric tons of CO2 equivalent

  • Net Leverage Ratio of 2.02x

  • Closed the previously announced acquisition of an incremental 25% ownership of the Power JV on January 30, 2026

  • Completed the underwritten public offering of approximately 7.0 million shares of common stock for net proceeds to BKV of $186.2 million

“We continued to deliver on our promises in the first quarter of 2026 through strong execution across the business and the achievement of several important milestones,” said Chris Kalnin, Chief Executive Officer of BKV. “During the quarter, we closed the BKV-BPP Power transaction, increasing our ownership in the joint venture to 75%, completed an equity offering, achieved first injection at our Cotton Cove CCUS project, and materially advanced our process toward a PPA at the Temple Energy Complex, all while maintaining operational excellence across our existing business lines.”

“We also continued to strengthen our positioning for long-term power growth with the announcement of 1.2 GW of turbine reservations and additional site control with 6,200 acres in North Central Texas and nearly 800 additional acres around our Temple facility,” continued Kalnin. “These actions, combined with the continued advancement of our closed loop strategy, position BKV to capitalize on the opportunities ahead and drive long-term value for our shareholders.”

Financial Results

 

Three Months Ended March 31,

($ Millions, except EPS)(1)

 

2026

 

 

2025

 

Net income (loss) attributable to BKV

$

44.1

 

$

(82.0

)

Adjusted Net Income attributable to BKV, non-GAAP

$

22.4

 

$

37.4

 

Adjusted EPS attributable to BKV, non-GAAP(2)

$

0.22

 

$

0.44

 

Adjusted EBITDAX attributable to BKV, non-GAAP

$

112.0

 

$

105.0

 

Net cash provided by operating activities

$

72.0

 

$

16.5

 

Net cash provided by operating activities before working capital

$

109.3

 

$

50.0

 

Adjusted Free Cash Flow before Power Growth attributable to BKV, non-GAAP

$

20.0

 

$

(28.5

)

Capital expenditures (accrued)

 

 

 

Development (3)

$

81.9

 

$

47.9

 

Power (4)

$

16.7

 

$

0.1

 

CCUS and other

$

20.0

 

$

10.1

 

Total capital expenditures (accrued)

$

118.6

 

$

58.1

 

 

 

(1) Adjusted Net Income attributable to BKV, Adjusted EPS attributable to BKV, Adjusted EBITDAX attributable to BKV, and Adjusted Free Cash Flow before Power Growth attributable to BKV are each non-GAAP financial measures. For a definition of each of these non-GAAP financial measures and reconciliations of such non-GAAP financial measures to their most directly comparable GAAP metrics, please see “Supplemental Non-GAAP Financial Measures” below.

(2) Reflects Adjusted EPS attributable to BKV on a diluted basis.

(3) Excludes asset retirement obligation expenditures of $0.6 million and $0.1 million for the three months ended March 31, 2026 and 2025, respectively.

(4) Power maintenance was $0.2 million and $0.1 million for the three months ended March 31, 2026 and 2025, respectively.

“Our first quarter results reflect a continued focus on disciplined capital allocation as we invest in growth across our platform,” said David Tameron, Chief Financial Officer of BKV. “We generated strong free cash flow from our base business and deployed capital strategically, while maintaining a solid balance sheet and substantial liquidity.”

“In addition, we successfully executed an equity offering to support the continued expansion of our power business, reinforcing our ability to fund strategic initiatives while preserving financial flexibility,” continued Tameron. “This balanced approach positions us to drive sustained growth while maintaining a strong financial foundation.”

Business Segment Results

 

Three Months Ended March 31, 2026

($ Thousands)

Upstream/

Midstream

 

Power

 

Corporate

& Other

 

Total

Income (loss) from operations

$

64,857

 

 

$

33,486

 

 

$

(12,317

)

 

$

86,026

 

Add back (subtract):

 

 

 

 

 

 

 

Depreciation, depletion, amortization, and accretion

 

41,915

 

 

 

11,804

 

 

 

446

 

 

 

54,165

 

Net unrealized derivative (gains) losses

 

16,136

 

 

 

(29,992

)

 

 

 

 

 

(13,856

)

Forward month gas settlement (1)

 

(23,445

)

 

 

 

 

 

 

 

 

(23,445

)

Equity-based compensation expense

 

2,032

 

 

 

625

 

 

 

1,250

 

 

 

3,907

 

Other income

 

1,513

 

 

 

800

 

 

 

575

 

 

 

2,888

 

Other nonrecurring transactions

 

5,383

 

 

 

3,707

 

 

 

 

 

 

9,090

 

Adjusted EBITDAX, non-GAAP

 

108,391

 

 

 

20,430

 

 

 

(10,046

)

 

 

118,775

 

(Deduct) add: Adjusted EBITDAX attributable to Noncontrolling Interests (2)

 

 

 

 

(5,877

)

 

 

(921

)

 

 

(6,798

)

Adjusted EBITDAX attributable to BKV, non-GAAP

$

108,391

 

 

$

14,553

 

 

$

(10,967

)

 

$

111,977

 

 

Three Months Ended March 31, 2025

($ Thousands)

Upstream/

Midstream

 

Power

 

Corporate

& Other

 

Total

Loss from operations

$

(79,685

)

 

$

(7,389

)

 

$

(13,023

)

 

$

(100,097

)

Add back (subtract):

 

 

 

 

 

 

 

Depreciation, depletion, amortization, and accretion

 

39,584

 

 

 

9,648

 

 

 

479

 

 

 

49,711

 

Net unrealized derivative (gains) losses

 

133,985

 

 

 

13,050

 

 

 

 

 

 

147,035

 

Forward month gas settlement (1)

 

3,997

 

 

 

 

 

 

 

 

 

3,997

 

Equity-based compensation expense

 

723

 

 

 

372

 

 

 

972

 

 

 

2,067

 

Impairment of asset held for sale

 

2,446

 

 

 

 

 

 

 

 

 

2,446

 

Other income (expense)

 

401

 

 

 

2,698

 

 

 

(65

)

 

 

3,034

 

Other nonrecurring transactions

 

1,100

 

 

 

 

 

 

455

 

 

 

1,555

 

Adjusted EBITDAX, non-GAAP

 

102,551

 

 

 

18,379

 

 

 

(11,182

)

 

 

109,748

 

(Deduct) add: Adjusted EBITDAX attributable to Noncontrolling Interests (2)

 

 

 

 

(4,746

)

 

 

 

 

 

(4,746

)

Adjusted EBITDAX attributable to BKV, non-GAAP

$

102,551

 

 

$

13,633

 

 

$

(11,182

)

 

$

105,002

 

 

 

(1) Natural gas derivative contracts settle and are realized in the month prior to the production covered by the contract. This adjustment removes the timing difference between the settlement date and the underlying production month that is hedged.

(2) Non-GAAP financial measure, see supplemental non-GAAP financial measures for reconciliations to the most comparable financial measures in accordance with GAAP.

Segment Operational Results – First Quarter 2026

Power Business Segment

BKV continues to make meaningful progress toward securing a long-term power purchase agreement (PPA) to enhance revenue visibility and optimize generation at the Power JV’s Temple plants. Through the previously disclosed advisor-led process, the Company is actively evaluating PPA proposals and remains engaged in discussions with multiple prospective counterparties.

The Company continues to evaluate multiple avenues for expansion, including modular power development and a private use network at the Temple complex, as well as a potential Temple III expansion and new project opportunities in North Central Texas. BKV has taken multiple measured steps to advance readiness to support speed to power and power growth, including entering into equipment supply contracts related to modular power, securing turbine reservations for up to 1.2 GW of capacity, gaining site control on nearly 800 additional acres in Temple, and acquiring approximately 6,200 acres of site control in North Central Texas. The pace and scale of future development and capital spending will be driven by progress in commercial discussions toward securing long-term PPAs. With power demand in the U.S. and ERCOT markets continuing to accelerate—driven by AI-enabled data center growth and increasing electrification—BKV is well positioned to capitalize on these structural trends.

Power segment Adjusted EBITDAX (“Power Adjusted EBITDAX”) was $20.4 million in the three months ended March 31, 2026, and $18.4 million for the three months ended March 31, 2025. Power Adjusted EBITDAX attributable to BKV was $14.6 million for the three months ended March 31, 2026, compared to $13.6 million for the three months ended March 31, 2025. Power Adjusted EBITDAX attributable to Noncontrolling Interests was $5.9 million in the three months ended March 31, 2026 and $4.7 million for the three months ended March 31, 2025.

The first quarter of 2026, was marked by a significant January cold weather event, Winter Storm Fern, that drove elevated demand and required sustained dispatch. Total power generation for the quarter increased 24.7% year over year. During this period, the plants operated reliably with no forced outages, leveraging gas from storage to enhance flexibility, optimize realizations, and support grid stability during a challenging and critical stress event. Outside of the January cold snap, weather conditions were relatively mild for the winter season, with heating degree days approximately 30% lower than the first quarter of 2025. Planned maintenance activities were successfully completed on both plants in March, reinforcing strong operational readiness heading into the remainder of the year.

On January 30, 2026, BKV successfully completed its acquisition of one-half of the ownership interests in the BKV-BPP Power JV then-held by Banpu Power US Corporation’s (“BPPUS”), increasing BKV’s ownership stake in the joint venture from 50% to 75%. The transaction allows BKV to consolidate the financial results of the JV as provided in this quarter’s updated financials. An updated governance structure adopted in connection with the transaction strengthens BKV’s ability to align power operations with its long-term growth strategy while supporting continued reliability of the Temple facilities.

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

 

2025

 

Temple I capacity factor

 

 

64.5

%

 

 

45.4

%

Temple II capacity factor

 

 

60.3

%

 

 

54.2

%

Total power generation (GWh)

 

 

1,981

 

 

 

1,588

 

Average power price ($/MWh)

 

$

51.04

 

 

$

52.87

 

Average natural gas cost

 

$

4.08

 

 

$

4.13

 

Average spark spread

 

$

22.21

 

 

$

23.67

 

 

 

 

 

 

Summary of Power Operations

 

 

 

 

($ Millions)

 

 

 

 

Total revenues, net

 

$

164.6

 

 

$

97.7

 

Depreciation and amortization

 

$

11.8

 

 

$

9.6

 

Operating expenses

 

$

119.3

 

 

$

95.4

 

Income (loss) from operations

 

$

33.5

 

 

$

(7.3

)

Interest expense, net

 

$

(13.5

)

 

$

(15.5

)

Other income

 

$

0.8

 

 

$

2.7

 

Net income (loss)

 

$

20.8

 

 

$

(20.1

)

Net income (loss) attributable to BKV

 

$

13.7

 

 

$

(15.4

)

Upstream, Midstream, and Commercial

BKV delivered strong operational performance in the first quarter, with production at the high-end of our guidance range while remaining within its capital framework. The upstream business continues to serve as a durable cash engine for the Company, generating consistent cash flow while improving capital efficiency across the asset base.

Results were driven by continued improvements in drilling and completions execution, including success from advanced completions designs that are outperforming prior type curves. The Company is also seeing benefits from positive offset well (“POW”) effects in the Barnett, where modern completion techniques are increasing production from both new and existing wells. Together, these initiatives are driving capital efficient incremental production and value without requiring capital expenditures beyond our budget. Additionally, BKV continues to enhance application of data and analytics, enabling management of its industry-leading low base decline and improving base production even further.

BKV also continues to expand its commercial capabilities. During the first quarter, the Company took over a substantive portion of its natural gas marketing and expects to be fully marketing its own production this year. Over time, this is expected to improve margins, increase commercial flexibility, and enhance BKV’s ability to deliver integrated solutions across gas, power, carbon sequestered gas, and LNG-related arrangements.

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

 

2025

 

Production

 

 

 

 

Net production per day (MMcfe/d)

 

 

925.0

 

 

 

761.1

 

Natural gas (MMcf)

 

 

68,079

 

 

 

54,121

 

NGL (MBbls)

 

 

2,490

 

 

 

2,344

 

Oil (MBbls)

 

 

39

 

 

 

53

 

Total (MMcfe)

 

 

83,253

 

 

 

68,503

 

Natural Gas ($/Mcf)

 

 

 

 

Average NYMEX Henry Hub price

 

$

5.04

 

 

$

3.65

 

Differential

 

$

(1.51

)

 

$

(0.55

)

Average realized prices, excluding derivatives

 

$

3.53

 

 

$

3.10

 

Average realized prices, including derivatives

 

$

3.14

 

 

$

2.86

 

NGLs ($/Bbl)

 

 

 

 

Average realized prices, excluding derivatives

 

$

17.98

 

 

$

19.06

 

Average realized prices, including derivatives

 

$

17.98

 

 

$

16.89

 

Oil ($/Bbl)

 

 

 

 

Average realized prices

 

$

70.87

 

 

$

65.28

 

Average Operating Cash Costs per Mcfe

 

 

 

 

Lease operating and workover

 

$

0.54

 

 

$

0.51

 

Taxes other than income

 

$

0.19

 

 

$

0.15

 

Gathering and transportation costs

 

$

0.81

 

 

$

0.81

 

Total

 

$

1.54

 

 

$

1.47

 

Carbon Capture Utilization and Sequestration (“CCUS”)

BKV achieved initial injection at its Cotton Cove project in April. Cotton Cove represents the Company’s second operational CCUS project and is expected to achieve a sequestration rate of approximately 32,000 metric tons of CO₂ per year.

The Barnett Zero Project sequestered approximately 35,800 metric tons of CO2 during the three months ended March 31, 2026. Since start-up in November 2023, the project has sequestered approximately 347,400 metric tons of CO2 through March 31, 2026.

BKV’s additional CCUS development projects are progressing on pace with our previously provided timelines and consistent with previously provided scope targets. The Eagle Ford project is on track to commence injection before June 30, 2026, with an expected sequestration rate of approximately 90,000 metric tons of CO₂ per year; the project has received EPA approval of its monitoring, reporting, and verification (MRV) plan. The East Texas project remains on track with a forecasted injection target of approximately 70,000 metric tons per year of CO2. As previously announced, BKV executed definitive agreements in the first quarter of 2026 with Comstock Resources to advance two CCUS projects at Comstock’s Bethel and Marquez natural gas processing facilities in the Western Haynesville. These developments and our broader pipeline of potential projects in our CCUS portfolio play a key role in supporting our targeted 1.5 million tons per annum injection run-rate by 2028.

BKV has received notice that its Class VI permit applications for the High West project have entered technical review with Louisiana regulators.

BKV is also continuing multiple Front-End Engineering Design (FEED) studies regarding CO2 capture from combined cycle natural gas turbines, like those at our Temple location, to further delineate capital and operating costs of such facilities. These studies are expected to be completed in 2026 and are intended to further inform potential power-related CCUS development opportunities across the Company’s portfolio.

Capital Expenditures

Accrued capital expenditures in the first quarter of 2026 were $118.6 million, which included $81.9 million for Upstream/Midstream development capital, $16.7 million for Power, and $20.0 million for CCUS and other expenditures. In addition, the Company spent an additional $33.1 million on deposits on fixed asset purchases in the quarter ending March 31, 2026, comprised of payments for turbines, modular generation equipment, and other long lead time items in Power included within our Strategic Power Growth capital expenditures and investments guidance. Accrued capital expenditures for the same period in 2025 were $58.1 million, which included $47.9 million for Upstream/Midstream development capital, $0.1 million for Power, and $10.1 million for CCUS and other expenditures.

Liquidity and Debt attributable to BKV

As of March 31, 2026, BKV had cash and cash equivalents of $288.5 million and restricted cash of $16.0 million related to the Power segment Temple Term Loan Facility. Total debt as of March 31, 2026 was $1.3 billion, which was made up of the 2030 Senior Notes of $500.0 million, RBL balance of $100.0 million, a promissory note of $46.0 million, and Power segment debt facilities of $635.4 million consisting of borrowings under the Temple I Loan Agreements of $176.0 million, borrowings under the Temple Term Loan Facility of $399.4 million, and Temple Revolving Facility balance of $60.0 million. s of March 31, 2026, total liquidity for BKV was $973.5 million, which consists of $288.5 million in cash and cash equivalents and $685.0 million available capacity under the Company’s RBL. RBL availability as of March 31, 2026, is based on the elected commitment amount of $800.0 million, less $15.0 million of letters of credit, less our outstanding balance of $100.0 million.

Second Quarter and Full Year 2026 Guidance

 

Q2 2026

 

FY 2026

Accrued Capital Expenditures and Net Production ($ Millions)

 

 

 

Development (1)

$35 – $55

 

$200 – $280

Power – Strategic Capital & Investments + Maintenance (1), (2)

$100 – $120

 

$280 – $340

CCUS and other (2)

$20 – $40

 

$90 – $120

Total capital expenditures

$155 – $215

 

$570 – $740

 

 

 

 

Net production (MMcfe/d)

925 – 975

 

915 – 955

 

 

 

 

Per Unit Operating Costs ($/Mcfe)

 

 

 

Lease operating and workover

$0.49 – $0.53

 

$0.49 – $0.53

Gathering, compression, processing, and transport (GCPT)

$0.80 – $0.84

 

$0.80 – $0.84

Upstream general and administrative (excl. stock comp)

$0.20 – $0.25

 

$0.20 – $0.25

 

 

 

 

Other General and Administrative Costs

 

 

 

General and administrative (Power, CCUS, & Other)

$15 – $18

 

$53 – $63

General and administrative (stock comp)

$4 – $6

 

$15 – $25

 

 

 

 

Commodity Prices

 

 

 

Average natural gas differential (3), (4)

$(0.70) – $(0.90)

 

$(0.65) – $(0.85)

NGL % of WTI

~ 27%

 

~ 24%

 

 

 

 

Power ($ Millions)

 

 

 

Power Adjusted EBITDAX

$30 – $40

 

$135 – $175

 

 

(1) 2026 maintenance capital: Upstream ~$200 million; Power ~$5 million

(2) Expecting $85 million – $105 million in JV partner capital contributions

(3) Differential includes $0.15/Mcfe – $0.20/Mcfe of gathering, compression, processing, and transport

(4) Differential includes $0.15/Mcfe – $0.25/Mcfe of ethane rejection impacts in the first half of 2026

First Quarter 2026 Earnings Conference Call

The Company plans to host a conference call to discuss results today, May 7, 2026 at 10 AM ET. To access the conference call, participants may dial (877) 407-0779 (US) or (201) 389-0914 (international). Participants can also listen to a live webcast of the call by going to the Investors section on the BKV website at www.ir.bkv.com. A replay will be available shortly after the live conference call and can be accessed on the Company’s website or by dialing (844) 512-2921 (US) or (412) 317-6671 (international). The passcode for the replay is 13759950. The replay will be available for 60 days after the call.

About BKV Corporation

Headquartered in Denver, Colorado, BKV Corporation is a forward-thinking, growth-driven energy company focused on creating value for its stockholders. BKV’s core business is to produce natural gas from its owned and operated upstream assets. BKV’s overall business is organized into four business lines: natural gas production; natural gas gathering, processing and transportation; power generation; and carbon capture, utilization and sequestration. BKV (and its predecessor entity) was founded in 2015, and BKV and its employees are committed to building a different kind of energy company. BKV is one of the top 20 gas-weighted natural gas producers in the United States and the largest natural gas producer by gross operated volume in the Barnett Shale. BKV Corporation is the parent company for the BKV family of companies. For more information, visit the BKV website at www.bkv.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, which are not historical facts, include statements regarding BKV’s strategy, future operations, financial position, estimated revenue and losses, projected costs, prospects, plans, objectives of management and dividend policy, and often contain words such as “expect,” “project,” “estimate,” “believe,” “anticipate,” “intend,” “budget,” “plan,” “seek,” “aspire,” “envision,” “forecast,” “target,” “predict,” “may,” “should,” “would,” “could,” “will,” and similar expressions. Actual results and future events could differ materially from those anticipated in such statements, and such forward-looking statements may not prove to be accurate. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits, opportunities and results with respect to the BKV-BPP Power Joint Venture Transaction, including any expected value creation from the BKV-BPP Power Joint Venture Transaction, anticipated efficiencies, power plant reliability, and strategic growth and power purchase agreement opportunities relating to the BKV-BPP Power Joint Venture and the BKV-BPP Power Joint Venture Transaction, as well as guidance, projected or forecasted financial and operating results, future liquidity, leverage, results in certain basins, objectives, project timing, utility of reporting segment changes, expectations and intentions, regulatory and governmental actions and other statements that are not historical facts. All forward-looking statements, expressed or implied, in this press release are based only on information currently available to BKV and speak only as of the date on which they are made. Forward-looking statements are not guarantees of future performance, and BKV cannot assure any reader that those statements will be realized or that the forward-looking events and circumstances will occur. Undue reliance should not be placed on any forward-looking statement, which is based on predictions of future results that may not occur as anticipated. Forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations, including but not limited to assumptions, risks and uncertainties regarding the BKV-BPP Power Joint Venture Transaction and the anticipated benefits thereof and the Bedrock Acquisition and the anticipated benefits thereof, as well as our ability to effectively operate and grow our CCUS business, expected increase in demand for power generation and our ability to serve that demand from our power business, our ability to develop, market and sell our carbon sequestered gas product; and management’s outlook guidance or forecasts of future events, including projected capital expenditures, production volumes, operating costs, pricing differentials, and Adjusted EBITDAX. For further discussions of risks and uncertainties applicable to forward-looking statements, you should refer to BKV’s filings with the Securities and Exchange Commission (the “SEC”), including the “Risk Factors” section of BKV’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q.

BKV Corporation

Condensed Consolidated Balance Sheets

($ thousands, except par value)

(Unaudited)

 

 

March 31, 2026

 

December 31, 2025 (1)

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

288,536

 

 

$

248,427

 

Restricted cash

 

15,974

 

 

 

15,846

 

Accounts receivable, net

 

141,722

 

 

 

129,077

 

Accounts receivable, related parties

 

11,282

 

 

 

11,196

 

Prepaid expenses

 

13,258

 

 

 

14,720

 

Inventory

 

18,761

 

 

 

20,039

 

Commodity derivative assets, current

 

72,216

 

 

 

63,900

 

Other current assets

 

6,245

 

 

 

8,150

 

Total current assets

 

567,994

 

 

 

511,355

 

Natural gas properties and equipment

 

 

 

Developed properties

 

3,016,204

 

 

 

2,965,638

 

Undeveloped properties

 

13,416

 

 

 

13,182

 

Midstream assets

 

278,340

 

 

 

277,974

 

Accumulated depreciation, depletion, and amortization

 

(884,546

)

 

 

(849,464

)

Total natural gas properties, net

 

2,423,414

 

 

 

2,407,330

 

Other property and equipment, net

 

1,057,960

 

 

 

944,412

 

Deposits

 

48,402

 

 

 

14,247

 

Goodwill

 

18,417

 

 

 

18,417

 

Commodity derivative assets

 

36,422

 

 

 

26,432

 

Other noncurrent assets

 

18,923

 

 

 

17,064

 

Total assets

$

4,171,532

 

 

$

3,939,257

 

 

 

 

 

Liabilities, mezzanine equity, and equity

 

 

 

Current liabilities

 

 

 

Accounts payable and accrued liabilities

$

217,441

 

 

$

229,487

 

Commodity derivative liabilities, current

 

17,526

 

 

 

8,469

 

Income taxes payable to related party

 

978

 

 

 

810

 

Payable to BPPUS for the BKV-BPP Power Joint Venture Transaction

 

 

 

 

115,136

 

Current portion of Temple I Loan Agreements

 

176,000

 

 

 

191,000

 

Current portion of long-term debt, net

 

9,387

 

 

 

9,387

 

Other current liabilities

 

11,248

 

 

 

10,302

 

Total current liabilities

 

432,580

 

 

 

564,591

 

Asset retirement obligations

 

197,014

 

 

 

230,372

 

Commodity derivative liabilities

 

1,160

 

 

 

5,767

 

Deferred tax liability, net

 

140,139

 

 

 

128,839

 

Long-term debt, net

 

1,080,913

 

 

 

937,724

 

Other noncurrent liabilities

 

8,638

 

 

 

5,223

 

Total liabilities

 

1,860,444

 

 

 

1,872,516

 

Commitments and contingencies

 

 

 

Mezzanine equity

 

 

 

Noncontrolling interest

 

18,622

 

 

 

12,951

 

Stockholders’ equity

 

 

 

Common stock, $0.01 par value; 500,000 authorized shares; 109,385 and 96,872 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

 

1,760

 

 

 

1,635

 

Treasury stock, shares at cost; 214 shares as of March 31, 2026 and December 31, 2025

 

(6,663

)

 

 

(6,663

)

Additional paid-in capital

 

1,864,963

 

 

 

1,676,785

 

Retained earnings

 

352,385

 

 

 

309,051

 

Total stockholders’ equity

 

2,212,445

 

 

 

1,980,808

 

Noncontrolling interest

 

80,021

 

 

 

72,982

 

Total equity

 

2,292,466

 

 

 

2,053,790

 

Total liabilities, mezzanine equity, and equity

$

4,171,532

 

 

$

3,939,257

 

 

 

(1) The financial information presented in the condensed consolidated financial statements has been retrospectively adjusted for the BKV-BPP Power Joint Venture Transaction, which was accounted for as a transaction between entities under common control, with prior periods recast as if the transaction had occurred at the beginning of the earliest period presented. For additional information, see Note 2 – Acquisition to our condensed consolidated financial statements included in our Quarterly Report on Form 10-Q for the period ended March 31, 2026.

BKV Corporation

Condensed Consolidated Statements of Operations

($ thousands, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

 

2025 (1)

Revenues and other operating income

 

 

 

 

Natural gas, NGL, and oil sales

 

$

287,675

 

 

$

216,126

 

Midstream revenues

 

 

2,296

 

 

 

2,771

 

Derivative gains (losses), net

 

 

53,109

 

 

 

(98,383

)

Marketing revenues

 

 

17,585

 

 

 

9,686

 

Section 45Q tax credits

 

 

3,060

 

 

 

3,307

 

Power revenues

 

 

68,990

 

 

 

43,864

 

Other

 

 

132

 

 

 

(1,305

)

Total revenues and other operating income

 

 

432,847

 

 

 

176,066

 

Operating expenses

 

 

 

 

Lease operating and workover

 

 

45,075

 

 

 

35,055

 

Fuel commodity costs

 

 

57,121

 

 

 

46,363

 

Purchased power

 

 

27,355

 

 

 

18,667

 

Taxes other than income

 

 

20,202

 

 

 

14,790

 

Gathering and transportation

 

 

67,802

 

 

 

55,793

 

Depreciation, depletion, amortization, and accretion

 

 

52,941

 

 

 

49,597

 

Power operating and maintenance

 

 

19,679

 

 

 

20,213

 

General and administrative

 

 

42,130

 

 

 

29,069

 

Other operating expenses

 

 

14,516

 

 

 

6,616

 

Total operating expenses

 

 

346,821

 

 

 

276,163

 

Income (loss) from operations

 

 

86,026

 

 

 

(100,097

)

Other income (expense)

 

 

 

 

Interest expense

 

 

(22,830

)

 

 

(16,049

)

Interest expense, related party

 

 

(4,269

)

 

 

(5,076

)

Interest income

 

 

1,498

 

 

 

749

 

Other income

 

 

2,888

 

 

 

3,034

 

Income (loss) before income taxes

 

 

63,313

 

 

 

(117,439

)

Income tax benefit (expense)

 

 

(11,469

)

 

 

30,668

 

Net income (loss)

 

 

51,844

 

 

 

(86,771

)

Less: net income (loss) attributable to noncontrolling interest

 

 

7,769

 

 

 

(4,792

)

Net income (loss) attributable to BKV

 

$

44,075

 

 

$

(81,979

)

 

 

 

 

 

Net income (loss) per common share attributable to BKV:

 

 

 

 

Basic

 

$

0.42

 

 

$

(0.97

)

Diluted

 

$

0.42

 

 

$

(0.97

)

 

 

 

 

 

Weighted average number of common shares outstanding:

 

 

 

 

Basic

 

 

102,018

 

 

 

84,706

 

Diluted

 

 

102,304

 

 

 

84,706

 

 

 

(1) The financial information presented in the condensed consolidated financial statements has been retrospectively adjusted for the BKV-BPP Power Joint Venture Transaction, which was accounted for as a transaction between entities under common control, with prior periods recast as if the transaction had occurred at the beginning of the earliest period presented. For additional information, see Note 2 – Acquisition to our condensed consolidated financial statements included in our Quarterly Report on Form 10-Q for the period ended March 31, 2026.

BKV Corporation

Condensed Consolidated Statements of Cash Flows

($ thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

 

2025(1)

Cash flows from operating activities:

 

 

 

 

Net income (loss)

 

$

51,844

 

 

$

(86,771

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

Depreciation, depletion, amortization, and accretion

 

 

54,165

 

 

 

49,711

 

Equity-based compensation expense

 

 

3,907

 

 

 

2,067

 

Deferred income tax expense (benefit)

 

 

11,300

 

 

 

(31,098

)

Unrealized (gains) losses on derivatives, net

 

 

(13,856

)

 

 

147,035

 

Impairment of asset held for sale

 

 

 

 

 

2,446

 

Settlement of contingent consideration

 

 

 

 

 

(20,000

)

Payments for the purchase of put options

 

 

 

 

 

(16,206

)

Other, net

 

 

1,905

 

 

 

2,850

 

Changes in operating assets and liabilities:

 

 

 

 

Accounts receivable, net

 

 

(13,443

)

 

 

(12,805

)

Accounts receivable, related party

 

 

(86

)

 

 

(262

)

Accounts payable and accrued liabilities

 

 

(23,470

)

 

 

(26,036

)

Other changes in operating assets and liabilities

 

 

(277

)

 

 

5,522

 

Net cash provided by operating activities

 

 

71,989

 

 

 

16,453

 

Cash flows from investing activities:

 

 

 

 

Asset acquisition

 

 

(93,414

)

 

 

 

Deposits on fixed asset purchases

 

 

(33,050

)

 

 

 

Capital expenditures

 

 

(106,527

)

 

 

(57,612

)

Proceeds from sales of assets

 

 

171

 

 

 

1,109

 

Other investing activities, net

 

 

 

 

 

257

 

Net cash used in investing activities

 

 

(232,820

)

 

 

(56,246

)

Cash flows from financing activities:

 

 

 

 

Proceeds from issuance of common stock, net of underwriting discounts and commissions

 

 

186,174

 

 

 

 

Acquisition of affiliate (common control)

 

 

(115,136

)

 

 

 

Payment of debt issuance costs

 

 

(892

)

 

 

 

Payments on Temple Term Loan Facility

 

 

(2,500

)

 

 

(2,500

)

Proceeds from Promissory Note

 

 

46,000

 

 

 

 

Payments on Temple I Loan Agreements

 

 

(15,000

)

 

 

 

Proceeds under RBL Credit Agreement

 

 

330,000

 

 

 

170,000

 

Payments on RBL Credit Agreement

 

 

(230,000

)

 

 

(135,000

)

Net share settlements, equity-based compensation

 

 

(2,055

)

 

 

(1,181

)

Cash contributions from noncontrolling interest

 

 

4,200

 

 

 

 

Common stock issued from employee purchase plan

 

 

277

 

 

 

 

Net cash provided by financing activities

 

 

201,068

 

 

 

31,319

 

Net increase (decrease) in cash, cash equivalents, and restricted cash

 

 

40,237

 

 

 

(8,474

)

Cash, cash equivalents, and restricted cash, beginning of period

 

 

264,273

 

 

 

96,998

 

Cash, cash equivalents, and restricted cash, end of period

 

$

304,510

 

 

$

88,524

 

 

 

(1) The financial information presented in the condensed consolidated financial statements has been retrospectively adjusted for the BKV-BPP Power Joint Venture Transaction, which was accounted for as a transaction between entities under common control, with prior periods recast as if the transaction had occurred at the beginning of the earliest period presented. For additional information, see Note 2 – Acquisition to our condensed consolidated financial statements included in our Quarterly Report on Form 10-Q for the period ended March 31, 2026.

Derivative Contract Volumes and Fair Values

The following tables summarize the Company’s outstanding derivative positions as of March 31, 2026 by commodity and contract type, including volume, pricing indices, or reference points, and associated fair values.

The following table summarizes the Company’s power derivatives:

Instrument

 

Units

 

Quantity

 

Pricing Index

 

Fair Value as of

March 31, 2026

($ thousands)

2026

 

 

 

 

 

 

 

 

Swap

 

MMBtu

 

6,132,000

 

 

HSC Gas Daily

 

$

(3,821

)

Power forwards – sales

 

MWh

 

876,000

 

 

ERCOT North

 

$

8,717

 

Heat rate call option

 

MMBtu

 

5,256,000

 

 

Various

 

$

25,827

 

Power forwards – purchases

 

MWh

 

(573,011

)

 

Various

 

$

(7,085

)

The following table represents natural gas commodity derivatives indexed to NYMEX Henry Hub pricing:

Instrument

 

MMBtu

 

Weighted

Average

Price

(USD)

 

Weighted

Average

Price Floor

 

Weighted

Average

Price

Ceiling

 

Fair Value as of

March 31, 2026

($ thousands)

2026

 

 

 

 

 

 

 

 

 

 

Swap

 

121,458,622

 

$

3.86

 

 

 

 

 

$

56,026

 

2027

 

 

 

 

 

 

 

 

 

 

Swap

 

98,958,854

 

$

3.99

 

 

 

 

 

$

20,643

 

Collars

 

37,662,319

 

 

 

$

3.57

 

$

4.00

 

$

(257

)

Call options

 

36,500,000

 

 

 

 

 

$

5.00

 

$

(11,750

)

Put options

 

36,500,000

 

 

 

$

3.00

 

 

 

$

10,295

 

2028

 

 

 

 

 

 

 

 

 

 

Swap

 

94,085,323

 

$

3.79

 

 

 

 

 

$

4,073

 

2029

 

 

 

 

 

 

 

 

 

 

Swap

 

34,675,000

 

$

3.60

 

 

 

 

 

$

(157

)

The following table represents natural gas basis derivatives by reference price listed below:

Instrument

 

Basis Reference Price

 

MMBtu

 

Weighted

Average Basis

Differential

 

Fair Value as of

March 31, 2026

($ thousands)

2026

 

 

 

 

 

 

 

 

Swap

 

Transco Leidy Basis

 

39,713,234

 

$

(0.79

)

 

$

1,541

 

Swap

 

HSC Basis

 

41,250,000

 

$

(0.32

)

 

$

5,209

 

Swap

 

Transco St 85 (Z4) Basis

 

27,500,000

 

$

0.62

 

 

$

3,220

 

Swap

 

NGPL TXOK Basis

 

35,794,014

 

$

(0.37

)

 

$

3,134

 

2027

 

 

 

 

 

 

 

 

Swap

 

Transco Leidy Basis

 

10,950,000

 

$

(0.76

)

 

$

(1,313

)

Swap

 

HSC Basis

 

7,300,000

 

$

(0.25

)

 

$

1,303

 

Swap

 

NGPL TXOK Basis

 

16,965,270

 

$

(0.31

)

 

$

1,559

 

2028

 

 

 

 

 

 

 

 

Swap

 

NGPL TXOK Basis

 

7,320,000

 

$

(0.76

)

 

$

(568

)

Swap

 

HSC Basis

 

10,980,000

 

$

(0.17

)

 

$

1,288

 

The following table summarizes the Company’s natural gas liquids derivatives position by product and reference price:

Instrument

 

Commodity Reference Price

 

Gallons

 

Weighted

Average Price

(USD)

 

Fair Value as of

March 31, 2026

($ thousands)

2026

 

 

 

 

 

 

 

 

Swap

 

OPIS Purity Ethane Mont Belvieu

 

102,240,321

 

$

0.25

 

$

432

 

Swap

 

OPIS IsoButane Mont Belvieu Non-TET

 

10,677,157

 

$

0.86

 

$

(2,087

)

Swap

 

OPIS Normal Butane Mont Belvieu Non-TET

 

17,555,154

 

$

0.82

 

$

(3,738

)

Swap

 

OPIS Propane Mont Belvieu Non-TET

 

61,367,542

 

$

0.69

 

$

(5,274

)

Swap

 

OPIS Natural Gasoline Mont Belvieu Non-TET

 

27,359,457

 

$

1.38

 

$

(12,071

)

2027

 

 

 

 

 

 

 

 

Swap

 

OPIS Purity Ethane Mont Belvieu

 

79,965,970

 

$

0.28

 

$

2,908

 

Swap

 

OPIS IsoButane Mont Belvieu Non-TET

 

8,864,077

 

$

0.82

 

$

(860

)

Swap

 

OPIS Normal Butane Mont Belvieu Non-TET

 

14,071,274

 

$

0.78

 

$

(1,452

)

Swap

 

OPIS Propane Mont Belvieu Non-TET

 

49,204,884

 

$

0.66

 

$

(2,739

)

Swap

 

OPIS Natural Gasoline Mont Belvieu Non-TET

 

22,107,531

 

$

1.28

 

$

(3,051

)

Supplemental Non-GAAP Financial Measures

This release includes the non-GAAP financial measures described below. These non-GAAP measures are intended to provide additional information only and should not be considered as alternatives to, or more meaningful than, net income (loss) attributable to BKV, basic and diluted EPS, net income (loss), net cash provided by operating activities, or any other measure calculated in accordance with GAAP.

As a result of the Company’s acquisition of an additional 25% ownership interest in and consolidation of the BKV-BPP Power JV as of January 30, 2026, the Company has adjusted its non-GAAP measures of Combined Adjusted EBITDAX, Adjusted Free Cash Flow, and Adjusted Free Cash Flow Margin. Beginning in the first quarter of 2026, the Company will disclose Adjusted Net Income (Loss) attributable to BKV, Adjusted EPS attributable to BKV, Adjusted EBITDAX, Adjusted EBITDAX attributable to BKV, Adjusted EBITDAX attributable to Noncontrolling Interests, Adjusted Free Cash Flow before Power Growth, and Adjusted Free Cash Flow before Power Growth attributable to BKV. Such non-GAAP measures have been presented in this release for the comparative period and have been calculated based on the definitions below.

Adjusted Net Income (Loss) Attributable to BKV and Adjusted EPS Attributable to BKV

The Company defines Adjusted Net Income (Loss) attributable to BKV as net income (loss) attributable to BKV before (i) net unrealized derivative (gains) losses, (ii) forward month gas settlements, (iii) impairment of assets held for sale, (iv) other nonrecurring transactions, and (v) the tax impact of these adjustments calculated using a 23% statutory rate. The Company defines Adjusted EPS attributable to BKV as Adjusted Net Income (Loss) attributable to BKV divided by diluted weighted average common shares outstanding.

We believe Adjusted Net Income (Loss) attributable to BKV and Adjusted EPS attributable to BKV are useful performance measures because they allow us to effectively evaluate our operating performance and results of operations from period to period and against our peers, without regard to our financing methods, corporate form, capital structure, or one-time events. We exclude the items listed above from net income (loss) attributable to BKV in arriving at Adjusted Net Income (Loss) attributable to BKV and Adjusted EPS attributable to BKV because these amounts can vary substantially from company to company within our industry depending upon accounting methods and book values of assets, capital structures, and the method by which the assets were acquired. Our presentation of Adjusted Net Income (Loss) attributable to BKV and Adjusted EPS attributable to BKV should not be construed as an inference that our results will be unaffected by unusual or non-recurring items. Other companies, including other companies in our industry, may not use Adjusted Net Income (Loss) attributable to BKV and Adjusted EPS attributable to BKV or may calculate this measure differently than as presented in this release, limiting its usefulness as a comparative measure.

The table below presents a reconciliation of Adjusted Net Income (Loss) attributable to BKV to net income (loss) attributable to BKV, our most directly comparable GAAP financial measure for the periods indicated.

 

Three Months Ended March 31,

($ Thousands, except EPS)

 

2026

 

 

 

2025

 

Net income (loss) attributable to BKV

$

44,075

 

 

$

(81,979

)

Adjustment to net income (loss) attributable to BKV:

 

 

 

Net unrealized derivative (gains) losses

 

(13,856

)

 

 

147,035

 

Forward month gas settlement (1)

 

(23,445

)

 

 

3,997

 

Impairment of asset held for sale

 

 

 

 

2,446

 

Other nonrecurring transactions

 

9,090

 

 

 

1,555

 

Total adjustments before taxes

 

(28,211

)

 

 

155,033

 

Tax effect of adjustments

 

6,489

 

 

 

(35,658

)

Total adjustments after taxes

 

(21,722

)

 

 

119,375

 

 

 

 

 

Adjusted Net Income (Loss) attributable to BKV

$

22,353

 

 

$

37,396

 

 

 

 

 

Adjusted EPS attributable to BKV:

 

 

 

Basic

$

0.22

 

 

$

0.44

 

Diluted

$

0.22

 

 

$

0.44

 

 

 

 

 

Basic weighted-average shares of common stock outstanding

 

102,018

 

 

 

84,706

 

Add dilutive effects of TRSUs

 

153

 

 

 

22

 

Add dilutive effects of PRSUs

 

133

 

 

 

 

Diluted weighted-average shares of common stock outstanding

 

102,304

 

 

 

84,728

 

 

 

(1) Natural gas derivative contracts settle and are realized in the month prior to the production covered by the contract. This adjustment removes the timing difference between the settlement date and the underlying production month that is hedged.

Adjusted EBITDAX, Adjusted EBITDAX Attributable to BKV, and Adjusted EBITDAX Attributable to Noncontrolling Interests

The Company defines Adjusted EBITDAX as income (loss) from operations before (i) depreciation, depletion, amortization, and accretion, (ii) net unrealized derivative (gains) losses, (iii) forward month gas settlement, (iv) equity-based compensation expense, (v) exploration and impairment expense, (vi) other income (expense) and (vii) other nonrecurring transactions. Adjusted EBITDAX attributable to BKV is defined as Adjusted EBITDAX less Adjusted EBITDAX attributable to Noncontrolling Interests.

The Company excludes the items listed above from income (loss) from operations in arriving at Adjusted EBITDAX because these amounts can vary substantially from company to company within our industry depending upon accounting methods and book values of assets, capital structures and the method by which the assets were acquired. Adjusted EBITDAX should not be considered as an alternative to, or more meaningful than, income (loss) from operations determined in accordance with GAAP. Certain items excluded from Adjusted EBITDAX are significant components in understanding and assessing a company’s financial performance, such as a company’s cost of capital and tax burden, as well as the historic costs of depreciable assets, none of which are reflected in Adjusted EBITDAX. Our presentation of Adjusted EBITDAX should not be construed as an inference that our results will be unaffected by unusual or non-recurring items. Other companies, including other companies in our industry, may not use Adjusted EBITDAX or may calculate this measure differently than as presented in this release, limiting its usefulness as a comparative measure.

Adjusted EBITDAX is a supplemental non-GAAP financial measure that is used by our management and external users of our consolidated financial statements, such as industry analysts, investors, lenders, rating agencies and others to more effectively evaluate our operating performance and results of operations from period to period and against our peers. We believe Adjusted EBITDAX is a useful performance measure because it allows us to effectively evaluate our operating performance and results of operations from period to period and against our peers, without regard to our financing methods, corporate form or capital structure.

The table below presents a reconciliation of Adjusted EBITDAX to income (loss) from operations, our most directly comparable GAAP financial measure for the periods indicated.

 

Three Months Ended March 31,

($ Thousands)

 

2026

 

 

 

2025

 

Income (loss) from operations

$

86,026

 

 

$

(100,097

)

Add back (subtract):

 

 

 

Depreciation, depletion, amortization, and accretion

 

54,165

 

 

 

49,711

 

Net unrealized derivative (gains) losses

 

(13,856

)

 

 

147,035

 

Forward month gas settlement (1)

 

(23,445

)

 

 

3,997

 

Equity-based compensation expense

 

3,907

 

 

 

2,067

 

Impairment of asset held for sale

 

 

 

 

2,446

 

Other income (expense)

 

2,888

 

 

 

3,034

 

Other nonrecurring transactions

 

9,090

 

 

 

1,555

 

Adjusted EBITDAX

 

118,775

 

 

 

109,748

 

(Deduct) add: Adjusted EBITDAX attributable to Noncontrolling Interests (2)

 

(6,798

)

 

 

(4,746

)

Adjusted EBITDAX attributable to BKV

$

111,977

 

 

$

105,002

 

 

 

(1) Natural gas derivative contracts settle and are realized in the month prior to the production covered by the contract. This adjustment removes the timing difference between the settlement date and the underlying production month that is hedged.

(2) Non-GAAP financial measure, see below for a reconciliation of this non-GAAP financial measure to the most comparable financial measure in accordance with GAAP.

The Company defines Adjusted EBITDAX attributable to Noncontrolling Interests as the proportionate share of Adjusted EBITDAX attributable to Noncontrolling Interests in the CCUS JV and the Power JV, our non-wholly owned consolidated subsidiaries. The table below reconciles Adjusted EBITDAX attributable to Noncontrolling Interests to net income (loss) attributable to Noncontrolling Interest, the most comparable financial measure in accordance with GAAP.

 

 

Three Months Ended March 31,

($ Thousands)

 

 

2026

 

 

 

2025

 

Net income (loss) attributable to noncontrolling interest

 

$

7,769

 

 

$

(4,792

)

Add back (subtract):

 

 

 

 

Interest expense, net

 

 

3,385

 

 

 

3,868

 

Depreciation and amortization

 

 

3,142

 

 

 

2,407

 

EBITDAX before adjustments

 

 

14,296

 

 

 

1,483

 

Net unrealized derivative (gains) losses

 

 

(7,498

)

 

 

3,263

 

Adjusted EBITDAX attributable to Noncontrolling Interests

 

$

6,798

 

 

$

4,746

 

Adjusted Free Cash Flow before Power Growth and Adjusted Free Cash Flow before Power Growth Attributable to BKV

We define Adjusted Free Cash Flow before Power Growth as net cash provided by operating activities, excluding cash paid for contingent consideration and changes in operating assets and liabilities, less total cash paid for capital expenditures (excluding leasehold costs and acquisitions), excluding strategic power growth capital expenditures. Adjusted Free Cash Flow before Power Growth attributable to BKV is defined as Adjusted Free Cash Flow before Power Growth, less Adjusted EBITDAX attributable to Noncontrolling Interests, with net interest expense attributable to noncontrolling interest added back, plus net contributions from noncontrolling interest.

Adjusted Free Cash Flow before Power Growth and Adjusted Free Cash Flow before Power Growth attributable to BKV are not measures of net cash provided by or used in operating activities as determined by GAAP. These measures are supplemental non-GAAP financial measures used by management and external users of our financial statements, including industry analysts, investors, lenders and rating agencies, to assess our ability to internally fund our capital program, service or incur additional debt and pay dividends. Adjusted Free Cash Flow before Power Growth reflects cash flow available to fund our capital program excluding strategic power growth capital expenditures, while Adjusted Free Cash Flow before Power Growth attributable to BKV further adjusts for noncontrolling interests to reflect amounts attributable to common shareholders. We believe these measures are useful indicators of liquidity because they facilitate period-over-period comparisons of cash flow provided by operating activities and our ability to internally fund our capital program (including acquisitions), reduce leverage, fund acquisitions and return capital to shareholders. Adjusted Free Cash Flow before Power Growth and Adjusted Free Cash Flow before Power Growth attributable to BKV should not be considered an alternative to, or more meaningful than, net income (loss) or net cash provided by (used in) operating activities determined in accordance with GAAP. Other companies, including those in our industry, may define these measures differently, limiting its usefulness as a comparative measure.

The table below presents our reconciliation of Adjusted Free Cash Flow before Power Growth and Adjusted Free Cash Flow before Power Growth attributable to BKV to net cash provided by operating activities, our most directly comparable GAAP financial measure for the periods indicated.

 

 

Three Months Ended March 31,

($ Thousands)

 

 

2026

 

 

 

2025

 

Net cash provided by operating activities

 

$

71,989

 

 

$

16,453

 

Cash paid for contingent consideration (1)

 

 

 

 

 

(20,000

)

Change in operating assets and liabilities

 

 

37,276

 

 

 

33,581

 

Cash paid for capital expenditures (excl. leasehold costs, acquisitions)

 

 

(106,527

)

 

 

(57,612

)

Strategic Power Growth capital expenditures

 

 

16,457

 

 

 

 

Adjusted Free Cash Flow before Power Growth

 

$

19,195

 

 

$

(27,578

)

Add back (subtract):

 

 

 

 

Adjusted EBITDAX attributable to Noncontrolling Interests

 

 

(6,798

)

 

 

(4,746

)

Net interest expense attributable to Noncontrolling Interests

 

 

3,385

 

 

 

3,868

 

Net contributions from Noncontrolling Interests

 

 

4,200

 

 

 

 

Adjusted Free Cash Flow attributable to BKV before Power Growth

 

$

19,982

 

 

$

(28,456

)

 

 

(1) Cash paid for contingent consideration is included as a deduction to arrive at net cash provided by operating activities and therefore, is added back for the purpose of computing Adjusted Free Cash Flow before Power Growth.

 

Investor Contacts:

Michael Hall

BKV Corporation

Vice President, Investor Relations

[email protected]

Patrick Freeman

BKV Corporation

Senior Director, Investor Relations

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Energy Other Energy Oil/Gas

MEDIA:

Logo
Logo

Lee Enterprises Reports Strong Second Quarter Results

95% YOY Adjusted EBITDA(1) growth in Q2
Digital revenue(2) represents 56% of total revenue in Q2
Improved capital structure; $53M in cash & interest rate(3) reduced to 5%
Reaffirms guidance of YOY Adjusted EBITDA growth in FY26

DAVENPORT, Iowa, May 07, 2026 (GLOBE NEWSWIRE) — Lee Enterprises, Incorporated (NASDAQ: LEE), a digital-first subscription platform providing high quality, trusted, local news, information and a major platform for advertising in 114 markets, today reported preliminary second quarter fiscal 2026 financial results(4) for the period ended March 29, 2026.

“Our second quarter results reflect continued momentum in the business and disciplined execution across our operations,” said Nathan Bekke, Lee’s President and Chief Executive Officer. “Adjusted EBITDA increased $7 million, or 95%, over the prior year quarter, marking our fourth consecutive quarter of Adjusted EBITDA growth on a comparable basis(5). Our 2026 results continue to benefit from insurance reimbursements related to last year’s cyber event, contributing $4 million to Adjusted EBITDA in the quarter. Excluding these reimbursements, our underlying operating performance still drove Adjusted EBITDA growth of 45% year-over-year, highlighting the strength of our core business. These results reinforce our confidence that we will deliver year-over-year Adjusted EBITDA growth in fiscal 2026, while highlighting the resilience, momentum and ongoing evolution of our business model.”

“In the quarter, we continued to take proactive steps to align our cost structure with the ongoing shift in our revenue mix,” added Bekke. “These actions include further optimization of our operating footprint, streamlining of workflows, reduction in corporate overhead and continued prioritization of investments that support digital growth. As a result, we are realizing meaningful efficiencies while maintaining our focus on delivering high-quality local journalism and content. We expect these efforts to continue supporting margin improvement and enhancing the scalability of our business over time.”

“We are also beginning to realize benefits from the strategic investment completed in February,” said Bekke. “The amendment to our credit agreement reduced our interest rate mid-quarter, which will drive meaningful interest expense savings going forward. We expect these savings to total approximately $18 million annually, or up to $90 million over the next five years, further strengthening our capital structure and enhancing our financial flexibility as we continue to invest in digital growth. Additionally, we finished the quarter with $53 million in cash on our balance sheet, up $49 million year-over-year. This improved liquidity, combined with lower interest expense, positions us well to accelerate our strategic priorities and further strengthen our balance sheet over time.”

“Net loss for the quarter totaled $2 million, an improvement of $10 million, or 86%, compared to the prior year quarter. The year-over-year improvement was driven by higher Adjusted EBITDA, lower interest expense following the strategic investment, and continued cost discipline,” added Bekke.

“Our progress continues to reflect the strength of our strategy and advances we are making in our digital transformation,” Bekke added. “We remain focused on expanding recurring digital revenue while maintaining disciplined cost management to support margin improvement. We are highly encouraged by our performance through the first half of the fiscal year and remain confident in our strategy and our ability to deliver continued growth in the quarters ahead.”


For the second quarter ended March 29, 2026:

  • Total operating revenue was $122 million.
  • Total Digital Revenue was $68 million and represented 56% of our total operating revenue.
  • Revenue from digital-only subscribers totaled $22 million. Digital-only subscription revenue increased 17% annually over the past three years. Digital-only subscribers totaled 591,000 at the end of the quarter.
  • Digital advertising and marketing services revenue represented 74% of our total advertising revenue and totaled $41 million. Amplified Digital® Agency revenue totaled $23 million in the quarter.
  • Digital services revenue, which is predominantly from BLOX Digital, totaled $5 million.
  • Total Print Revenue was $54 million.
  • Operating expenses totaled $114 million and Cash Costs(1) totaled $112 million, representing 20% and 15% decreases compared to the prior year, respectively. During the quarter, operating expenses were reduced by $4 million due to business interruption insurance recoveries(6), recorded in the Insurance proceeds line item and included in Adjusted EBITDA. Operating expenses were further reduced by $1 million from insurance recoveries related to expenses incurred in response to the prior year cyber incident, recorded in Restructuring costs and other. Excluding these business interruption insurance proceeds and expense reimbursements, operating expenses decreased 17% compared to the prior year.
  • Net loss totaled $2 million, an improvement of $10 million, or 86%, over the prior year quarter.
  • Adjusted EBITDA totaled $15 million, an increase of $7 million, or 95%, over the prior year quarter.


2026 Fiscal Year Outlook:

Adjusted EBITDA YOY growth in the mid-single digits
   


Debt and Free Cash Flow:

The Company has $455 million of debt outstanding under our Credit Agreement with BH Finance. The financing has favorable terms including a 25-year maturity, a fixed annual interest rate, no fixed principal payments, and no financial performance covenants. The $50 million private placement of common stock closed in February 2026 made operative certain amendments to the Credit Agreement with BH Finance, resulting in the fixed annual interest rate dropping to 5% from 9% for a five-year period(3).

As of and for the period ended March 29, 2026:

  • The principal amount of debt totaled $455 million.
  • Cash on the balance sheet totaled $53 million. Debt, net of cash on the balance sheet, totaled $402 million.
  • Capital expenditures totaled $1 million for the quarter. We expect up to $8 million of capital expenditures in FY26.
  • We expect cash paid for income taxes to total between $2 million and $8 million in FY26.
  • We do not expect any pension contributions in the fiscal year.
  • The Company is executing a strategic termination of our fully funded benefit pension plan, eliminating the long-term volatility tied to interest rate movement, mortality assumptions and asset performance, while preserving participant benefits and improving balance sheet flexibility.


Conference Call Information:

As previously announced, we will hold an earnings conference call and audio webcast today at 9 a.m. Central Time. The live webcast will be accessible at www.lee.net and will be available for replay 24 hours later. Questions from other participants may be submitted by participating in the webcast. To participate in the live conference call via telephone, please register at www.lee.net. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.


About Lee:

Lee Enterprises is a leading provider of local news and information and a major subscription and advertising platform, with daily and weekly newspapers and rapidly expanding digital products serving 114 markets across 25 states. Lee’s markets include St. Louis, MO; Buffalo, NY; Omaha, NE; Richmond, VA; Lincoln, NE; Madison, WI; Davenport, IA; and Tucson, AZ. Lee Common Stock is traded on NASDAQ under the symbol LEE. For more information about Lee, please visit www.lee.net.

FORWARD-LOOKING STATEMENTS — The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. This release contains information that may be deemed forward-looking that is based largely on our current expectations, and is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those anticipated. Among such risks, trends and other uncertainties, which in some instances are beyond our control, are:

  • Our ability to manage declining print revenue and circulation subscribers;
  • The impact and duration of adverse conditions in certain aspects of the economy affecting our business;
  • Changes in advertising and subscription demand;
  • Changes in technology that impact our ability to deliver digital advertising;
  • Potential changes in newsprint, other commodities and energy costs;
  • Interest rates;
  • Labor costs;
  • Significant cyber security breaches or failure of our information technology systems;
  • Our ability to achieve planned expense reductions and realize the expected benefit of our acquisitions;
  • Our ability to maintain employee and customer relationships;
  • Our ability to manage increased capital costs;
  • Our ability to maintain our listing status on NASDAQ;
  • Competition;
  • We may be required to indemnify the previous owners of BH Media or The Buffalo News for unknown legal and other matters that may arise;
  • The impacts of changes to our leadership and corporate governance; and
  • Other risks detailed from time to time in our publicly filed documents.

Any statements that are not statements of historical fact (including statements containing the words “may”, “will”, “would”, “could”, “believes”, “expects”, “anticipates”, “intends”, “plans”, “projects”, “considers” and similar expressions) generally should be considered forward-looking statements. Statements regarding our plans, strategies, prospects and expectations regarding our business and industry and our responses thereto may have on our future operations, are forward-looking statements. They reflect our expectations, are not guarantees of performance and speak only as of the date the statement is made. Readers are cautioned not to place undue reliance on such forward-looking statements, which are made as of the date of this report. We do not undertake to publicly update or revise our forward-looking statements, except as required by law.

Contact:
[email protected]
(563) 383-2100

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)
 
  Three months ended Six months ended
(Thousands of Dollars, Except Per Common Share Data) March 29,
2026
March 30,
2025
March 29,
2026
March 30,
2025
         
Operating revenue:        
Print advertising revenue 14,274   16,532   31,465   36,393  
Digital advertising revenue 40,693   43,941   83,488   90,670  
Advertising and marketing services revenue 54,967   60,473   114,953   127,063  
Print subscription revenue 32,902   41,079   67,898   84,511  
Digital subscription revenue 22,279   23,789   44,985   45,354  
Subscription revenue 55,181   64,868   112,883   129,865  
Print other revenue 7,032   7,213   14,578   15,101  
Digital other revenue 4,784   4,826   9,612   9,913  
Other revenue 11,816   12,039   24,190   25,014  
Total operating revenue 121,964   137,380   252,026   281,942  
Operating expenses:        
Compensation 46,745   56,659   96,178   116,913  
Newsprint and ink 2,520   3,111   5,483   6,727  
Other operating expenses 62,750   71,455   131,564   146,135  
Insurance proceeds (3,840 )   (5,840 )  
Depreciation and amortization 3,515   5,171   7,094   11,436  
(Gain) loss on asset sales, impairments and other, net (900 ) 126   (903 ) (803 )
Restructuring costs and other 3,640   6,516   6,788   11,666  
Total operating expenses 114,430   143,038   240,364   292,074  
Equity in earnings of associated companies 1,008   1,155   2,088   2,277  
Operating income (loss) 8,542   (4,503 ) 13,750   (7,855 )
Non-operating (expense) income:        
Interest expense (7,629 ) (9,950 ) (17,877 ) (20,232 )
Pension and OPEB related benefit and other, net 826   658   1,671   1,311  
Curtailment/Settlement gains        
Total non-operating expense, net (6,803 ) (9,292 ) (16,206 ) (18,921 )
Income (loss) before income taxes 1,739   (13,795 ) (2,456 ) (26,776 )
Income tax expense (benefit) 3,448   (1,780 ) 4,379   1,463  
Net loss (1,709 ) (12,015 ) (6,835 ) (28,239 )
Net loss attributable to non-controlling interests (439 ) (496 ) (924 ) (1,020 )
Loss attributable to Lee Enterprises, Incorporated (2,148 ) (12,511 ) (7,759 ) (29,259 )
Other comprehensive loss, net of income taxes (79 ) (115 ) (158 ) (230 )
Comprehensive loss attributable to Lee Enterprises, Incorporated (2,227 ) (12,626 ) (7,917 ) (29,489 )
Loss per common share:        
Basic: (0.16 ) (2.07 ) (0.78 ) (4.87 )
Diluted: (0.16 ) (2.07 ) (0.78 ) (4.87 )

DIGITAL / PRINT REVENUE COMPOSITION

(UNAUDITED)
 
  Three months Ended Six months ended
(Thousands of Dollars) March 29,
2026
March 30,
2025
March 29,
2026
March 30,
2025
         
Digital Advertising and Marketing Services Revenue 40,693 43,941 83,488 90,670
Digital Only Subscription Revenue 22,279 23,789 44,985 45,354
Digital Services Revenue 4,784 4,826 9,612 9,913
Total Digital Revenue 67,756 72,556 138,085 145,937
Print Advertising Revenue 14,274 16,532 31,465 36,393
Print Subscription Revenue 32,902 41,079 67,898 84,511
Other Print Revenue 7,032 7,213 14,578 15,101
Total Print Revenue 54,208 64,824 113,941 136,005
Total Operating Revenue 121,964 137,380 252,026 281,942



RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(UNAUDITED)

The tables below reconcile the non-GAAP financial performance measure of Adjusted EBITDA to Net loss, its most directly comparable U.S. GAAP measure:

 
  Three months ended Six months ended
(Thousands of Dollars) March 29, 2026 March 30, 2025 March 29, 2026 March 30, 2025
         
Net loss (1,709 ) (12,015 ) (6,835 ) (28,239 )
Adjusted to exclude        
Income tax expense (benefit) 3,448   (1,780 ) 4,379   1,463  
Non-operating expenses, net 6,803   9,292   16,206   18,921  
Equity in earnings of TNI and MNI (1,008 ) (1,155 ) (2,088 ) (2,277 )
Depreciation and amortization 3,515   5,171   7,094   11,436  
Restructuring costs and other 3,640   6,516   6,788   11,666  
(Gain) loss on asset sales, impairments and other, net (900 ) 126   (903 ) (803 )
Stock compensation 213   358   541   788  
Add:        
Ownership share of TNI and MNI EBITDA (50%) 1,123   1,255   2,224   2,422  
Adjusted EBITDA 15,125   7,768   27,406   15,377  

The table below reconciles the non-GAAP financial performance measure of Cash Costs to Operating expenses, the most directly comparable U.S. GAAP measure:

  Three months ended Six months ended
(Thousands of Dollars) March 29, 2026 March 30, 2025 March 29, 2026 March 30, 2025
         
Operating expenses 114,430   143,038 240,364   292,074  
Adjustments        
Depreciation and amortization 3,515   5,171 7,094   11,436  
(Gain) loss on asset sales, impairments and other, net (900 ) 126 (903 ) (803 )
Restructuring costs and other 3,640   6,516 6,788   11,666  
Insurance proceeds (3,840 ) (5,840 )  
Cash Costs 112,015   131,225 233,225   269,775  

The table below reconciles the non-GAAP financial performance measure of Same-store Revenues to Operating Revenues, its most directly comparable U.S. GAAP measure:

  Three months ended Six months ended
(Thousands of Dollars) March 29,
2026
March 30,
2025
March 29,
2026
March 30,
2025
         
Print Advertising Revenue 14,274   16,532   31,465   36,393  
Exited operations (568 ) (2,108 ) (2,400 ) (4,487 )
Same-store, Print Advertising Revenue 13,706   14,424   29,065   31,906  
Digital Advertising Revenue 40,693   43,941   83,488   90,670  
Exited operations (168 ) (1,483 ) (770 ) (3,060 )
Same-store, Digital Advertising Revenue 40,525   42,458   82,718   87,610  
Total Advertising Revenue 54,967   60,473   114,953   127,063  
Exited operations (736 ) (3,590 ) (3,169 ) (7,548 )
Same-store, Total Advertising Revenue 54,231   56,883   111,784   119,515  
Print Subscription Revenue 32,902   41,079   67,898   84,511  
Exited operations   (50 ) (2 ) (109 )
Same-store, Print Subscription Revenue 32,902   41,029   67,896   84,402  
Digital Subscription Revenue 22,279   23,789   44,985   45,354  
Exited operations     (1 ) (2 )
Same-store, Digital Subscription Revenue 22,279   23,789   44,984   45,352  
Total Subscription Revenue 55,181   64,868   112,883   129,865  
Exited operations   (50 ) (3 ) (111 )
Same-store, Total Subscription Revenue 55,181   64,818   112,880   129,754  
Print Other Revenue 7,032   7,213   14,578   15,101  
Exited operations        
Same-store, Print Other Revenue 7,032   7,213   14,578   15,101  
Digital Other Revenue 4,784   4,826   9,612   9,913  
Exited operations        
Same-store, Digital Other Revenue 4,784   4,826   9,612   9,913  
Total Other Revenue 11,816   12,039   24,190   25,014  
Exited operations        
Same-store, Total Other Revenue 11,816   12,039   24,190   25,014  
Total Operating Revenue 121,964   137,380   252,026   281,942  
Exited operations (736 ) (3,640 ) (3,172 ) (7,658 )
Same-store, Total Operating Revenue 121,228   133,740   248,854   274,284  
                 

NOTES

(1) The following are non-GAAP (Generally Accepted Accounting Principles) financial measures for which reconciliations to relevant U.S GAAP measures are included in tables accompanying this release:

  • Adjusted EBITDA is a non-GAAP financial performance measure that enhances financial statement users overall understanding of the operating performance of the Company. The measure isolates unusual, infrequent or non-cash transactions from the operating performance of the business. This allows users to easily compare operating performance among various fiscal periods and how management measures the performance of the business. This measure also provides users with a benchmark that can be used when forecasting future operating performance of the Company that excludes unusual, nonrecurring or one-time transactions. Adjusted EBITDA is a component of the calculation used by stockholders and analysts to determine the value of our business when using the market approach, which applies a market multiple to financial metrics. It is also a measure used to calculate the leverage ratio of the Company, which is a key financial ratio monitored and used by the Company and its investors. Adjusted EBITDA is defined as net income (loss), plus non-operating expenses, income tax expense, depreciation and amortization, assets loss (gain) on sales, impairments and other, restructuring costs and other, stock compensation and our 50% share of EBITDA from TNI and MNI, minus equity in earnings of TNI and MNI.
  • Cash Costs represent a non-GAAP financial performance measure of operating expenses which are measured on an accrual basis and settled in cash. This measure is useful to investors in understanding the components of the Company’s cash-settled operating costs. Periodically, the Company provides forward-looking guidance of Cash Costs, which can be used by financial statement users to assess the Company’s ability to manage and control its operating cost structure. Cash Costs are defined as compensation, newsprint and ink and other operating expenses. Depreciation and amortization, assets loss (gain) on sales, impairments and other, other non-cash operating expenses and other expenses are excluded. Cash Costs also exclude restructuring costs and other, which are typically paid in cash.

(2) Total Digital Revenue is defined as digital advertising and marketing services revenue (including Amplified Digital®), digital-only subscription revenue and digital services revenue.

(3) The Company’s debt is the $576 million term loan under a credit agreement with BH Finance LLC dated January 29, 2020 (the “Credit Agreement”). Excess Cash Flow was previously defined under the Credit Agreement as any cash greater than $20.0 million on the balance sheet in accordance with U.S. GAAP at the end of each fiscal quarter, beginning with the quarter ending June 28, 2020. Concurrently with the execution of the Stock Purchase Agreement, we entered into the Second Amendment to the Credit Agreement. The amendments set forth therein became operative upon the Company’s receipt of the proceeds from the Private Placement at the Closing. The amendments include a reduction of the applicable margin on our 25-year term loan from 9% to 5% for a period of five years following the closing and amending the definition of Excess Cash Flow such that the minimum amount of cash on hand held by us before being deemed Excess Cash Flow would be equal to $64.0 million.

(4) This earnings release is a preliminary report of results for the periods included. The reader should refer to the Company’s most recent reports on Form 10-Q and on Form 10-K for definitive information.

(5) Comparable basis is a non-GAAP performance measure based on U.S. GAAP trends for Lee for the current period, excluding the extra week in fiscal 2024. The fourth quarter and full year of fiscal 2025 consisted of 13 weeks and 52 weeks, respectively. The fourth quarter and full year of fiscal 2024 consisted of 14 weeks and 53 weeks, respectively.

(6) FY25 revenue and Adjusted EBITDA were materially impacted by a cyber incident in February 2025. The FY25 impact on revenue and Adjusted EBITDA was approximately $12M and $8M, respectively. These metrics exclude any potential reimbursement from cyber insurance carrier in FY25. For the six months ended March 29, 2026, we received $5.8 million in business interruption reimbursements that were recorded on their own line in “Operating Expenses” and included in Adjusted EBITDA. The remaining business-interruption claims remain under review.

(7) TNI refers to TNI Partners publishing operations in Tucson, AZ. MNI refers to Madison Newspapers, Inc. publishing operations in Madison, WI.



Shift4 Announces First Quarter 2026 Results

Shift4 Announces First Quarter 2026 Results

CENTER VALLEY, Pa.–(BUSINESS WIRE)–
Shift4 (NYSE: FOUR) has posted its first quarter 2026 financial results as part of its Q1 2026 Shareholder Letter, which can be viewed here or by navigating to the Financials section of its Investor Relations website at https://investors.shift4.com.

Earnings Conference Call

Management will host a conference call today, May 7th, 2026, at 8:30 a.m. ET to discuss the results.

Conference Call Details

Toll-free dial-in:

 

+1-800-274-8461

Toll dial-in:

 

+1-203-518-9814

Conference ID:

 

FOUR1Q26

The earnings conference call will also be webcast live and interested parties can join the live webcast through Shift4’s website at: https://investors.shift4.com

X Spaces Simulcast

As previously announced, the live audio of the earnings call will be simulcast via X Spaces. Follow @Shift4 on X for additional information on how to access the simulcast.

About Shift4

Shift4 (NYSE: FOUR) powers the experience economy, enabling businesses to deliver the moments that matter. Transforming how people shop, dine, stay, and play, Shift4’s commerce technology allows for a seamless experience at any scale. From your neighborhood restaurant to the world’s largest event venues, Shift4 handles billions of transactions annually for hundreds of thousands of businesses around the world. For more information, visit shift4.com.

Investor Relations

Thomas McCrohan

EVP, Head of Investor Relations

Shift4

(484) 735-0779

[email protected]

Paloma Pate

Director, Strategy and Investor Relations

Shift4

(484) 954-5768

[email protected]

Media Contact

Nate Hirshberg

SVP, Marketing

Shift4

[email protected]

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Professional Services Payments Technology Software Finance Electronic Commerce Fintech

MEDIA:

Logo
Logo